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Abstract 
 
Mycoplasma felis is frequently isolated from cats showing signs of respiratory or 
ocular infection however its role as a pathogen is still undefined.  Some evidence 
suggests that M. felis may be a pathogen in ocular infections however evidence 
for pathogenic involvement of respiratory isolates is far less definitive.  Ocular 
clinical isolates were cultured to identify phenotype; antimicrobial susceptibility 
and haemolytic activity.  The strains were then sequenced along with a 
reference strain using Next Generation Sequencing technology, to determine if 
phenotype could be correlated with genotype and identify any genetic potential 
for virulence. 
 
Six antimicrobials were tested to identify antimicrobial resistance on a range of 
isolates and the reference strain NCTC 10160.  Fluoroquinolones were the most 
effective; however, recommendations state these should be employed 
conservatively as a third line antimicrobial, due to their importance in human 
medicine.  Tetracyclines, the first line of treatment in M. felis infection, were 
also effective with MIC90s of 0.06 µg/mL and 1 µg/mL for doxycycline and 
oxytetracycline, respectively. Little variance was observed between isolates, 
with only macrolides showing decreased efficacy.  The reference isolate NCTC 
10160 (from 1967) demonstrated the same susceptibility as the clinical isolates 
(2008-2014) and so this was not considered to be novel or emerging resistance.  
Haemolytic activity was observed in all isolates. 
 
The clinical isolates were sequenced using Next Generation Sequencing 
technology to establish if the observed phenotype correlated with a specific 
genotype.  No antimicrobial resistance markers were identified.  Upon alignment 
with a reference genome (M. cynos C142) several genes shared sequence 
homology with good coverage, including those involved in nutrient uptake and 
lipoprotein signalling; however, no definitive markers of virulence were 
identified. 
 
The generated MIC data will be useful as currently there are no established 
breakpoints in animal mycoplasmas. The MIC data available is limited and 
previously has been generated from research projects such as this.  Overall, the 
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pathogen status of M. felis is still unclear. No antimicrobial resistance markers 
or known virulence markers were identified in this study, although the genes 
used for alignments were not exhaustive and the highly mutable genome of 
mycoplasmas may mean divergent or novel resistance genes are present.  
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Chapter I 
Introduction 
1.1 Introduction to Mycoplasmas 
Controversy and contradiction have been at the forefront of mycoplasma 
research since the organisms were first described in 1889 (Frank, 1889).  Issues 
surrounded first the name itself (Krass and Gardner, 1973), quickly followed by 
questions surrounding their classification, morphology and pathogenicity (Barile 
and Razin, 1979).  These wall-less mollicutes, confirmed as the smallest known 
organisms capable of self-replication, and holding a minute, minimalist genome 
(Rottem, 2003, Carvalho et al., 2005) are curiosities in the field of microbiology. 
The mycoplasmas seem to be ubiquitous, having been isolated from most 
creatures, including horses (Wood et al., 1997), fish (Kirchhoff and Rosengarten, 
1984), turtles (Salinas et al., 2011), and even from plants and insects (Garnier et 
al., 2001).  There does seem to be a degree of host specificity for each 
mycoplasma species, with typical associations having been identified - 
Mycoplasma pneumoniae in humans, M. agassizii in turtles (Salinas et al., 2011), 
M. hyopneumoniae in pigs (Ciprian et al., 1988), M. gallisepticum in poultry 
(Khalifa et al., 2013) and M. felis in cats (Cole et al., 1967). 
The parasitic relationship between mycoplasmas and their host may be 
attributed to their minute genome size, which limits their capacity to synthesise 
the proteins and nucleic acids essential for growth and reproduction (Rottem, 
2003, Carvalho et al., 2005).  This limited biosynthesis also makes mycoplasma 
species fastidious and difficult to culture.  Despite this, they have proven to be a 
common and dreaded pest amongst researchers using cell and tissue culture, 
with between 15-35% of established cell lines being infected with mycoplasmas, 
as reviewed by Drexler et al. (2002).  
Symptoms of mycoplasmosis are variable depending on the particular 
mycoplasma species involved in infection, the host species, and the presence of 
any co-infections.  The organisms are known to colonise epithelial and mucosal 
tissues throughout the body, therefore infection is frequently associated with 
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respiratory symptoms or conjunctivitis, although mastitis, neurosystemic and 
arthritic symptoms have been recorded. 
More than 120 mycoplasma species have been isolated to date (Brown et al., 
2011).  Most have been identified as commensal organisms; however, some clear 
primary pathogens such as Mycoplasma mycoides subspecies mycoides SC (small 
colony), the aetiological agent of contagious bovine pleuropneumonia 
(CBPP)(Westberg et al., 2004), and M. genitalium, isolated in cases of human 
pelvic inflammatory disease (Blanchard and Bebear, 2011), have also been 
identified.  Primary pathogens seem to be the focus of most research, possibly 
due to the high impact to public health and costs associated with livestock 
sickness.  Other species have been utilised in molecular and cellular biology 
research, the lack of cell wall and minimal genome making them ideal models 
for research (Fraser et al., 1995, Rocha and Blanchard, 2002, Gibson et al., 
2008). 
1.2 Mycoplasma felis 
This study will focus on M. felis, which was first isolated from a case of feline 
conjunctivitis in 1967.  Early research attempted to determine the pathogenicity 
of M. felis as a respiratory and ocular pathogen, however evidence was 
inconsistent, with Koch’s postulates being established in some studies (Cole et 
al., 1967) but not others (Switzer, 1964), with no definitive explanation for 
variance. Reviewing the research to date, it seems to be accepted that ocular 
isolates of M. felis are pathogenic, with multiple publications associating the 
isolation of M. felis with the clinical presentation of conjunctivitis but with no 
reports of isolation from healthy cats (Shewen et al., 1980, Haesebrouck et al., 
1991b, Espínolaz and Lilenbaum, 1996, Hartmann et al., 2010).  Isolation from 
respiratory samples remains inconclusive; with M. felis being isolated from cats 
presenting with respiratory signs, but also from clinically healthy cats (Tan et 
al., 1977, Haesebrouck et al., 1991b, Low et al., 2007, Veir et al., 2008, 
Kompare et al., 2013) suggesting the organism to be an opportunistic 
commensal.  Mycoplasma felis has also proven to be highly antigenic with some 
studies describing seroconversion in almost all cats tested (Binns et al., 2000, 
Holst et al., 2010), which also suggests frequent exposure. 
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1.3 Gene Sequencing 
The revolutionary discovery of the structure and function of DNA in 1953 
(Watson and Crick, 1953) opened up many possibilities in genetic research and 
development.  Within fifteen years, the dideoxy method of determining 
nucleotide sequences now known as “Sanger sequencing”, (Sanger et al., 1977) 
was established and the first genome had been sequenced, proving that 
sequence generation and the subsequent genetic organisation it identified, could 
provide new and relevant insight for researchers. Sanger sequencing is the basis 
of many current sequencing technologies and was instrumental in the 
development of the discipline of bioinformatics, an essential advancement in 
sequencing analysis (McCallum and Smith, 1977, Dayhoff et al., 1981, Bilofsky et 
al., 1986, Pearson and Lipman, 1988, Altschul et al., 1990, Staden et al., 2000).  
Although further developed now, Sanger sequencing is not without issues; the 
limited size of DNA fragments which can be sequenced (~1000 bp) making it a 
time consuming and costly exercise; Sanger sequencing was employed to 
sequence the first full human genome – it took around ten years and cost almost 
3 billion dollars (Venter et al., 2001). 
Sequencing technologies and analysis tools and databases are now so advanced 
that genome sequencing is being utilised by researchers worldwide to sequence 
genomes from a multitude of organisms for purposes as widespread as 
investigating the genetic basis of antibiotic resistance in bacteria, to identifying 
genetic mutations that correlate with disease phenotypes in humans (Morozova 
and Marra, 2008, van El et al., 2013).    
Next Generation Sequencing (NGS) technology provided a solution to the 
limitations of Sanger sequencing; namely scalability, speed and throughput by 
employing massively parallel sequencing, capable of processing millions of 
reactions simultaneously thus generating huge volumes of data (Illumina, 2012). 
Although numerous platforms are available from biotechnology developers such 
as Illumina and Roche, the basic principles remain the same; fragment the target 
genome, generate a DNA library and the analyser will provide the nucleotide 
sequence of the fragments. 
This simplistic principle however, is not without qualifications.  The quality of 
the NGS data generated may be affected by an array of things, with library 
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preparation being critical to obtaining good quality data.  The concentration, 
size distribution, nucleotide composition and amplification of the template DNA 
may all influence the quality of data output.  Given that DNA yield is variable 
depending on the quality of the sample and the organism from which it is 
obtained, kits have been developed that not only allow multiple samples to be 
sequenced simultaneously using indexes (multiplexing), but also accommodate 
picogram concentrations of DNA template where DNA input is limited. 
Analysers may generate their own quality control data.  For example the 
Illumina MiSeq, which was used in this study, provides a “Q Score” indicative of 
whether a nucleotide has been correctly identified during sequencing.  It is 
acknowledged that sequence quality diminishes towards the end of a read; 
however technology is under constant development and this is always being 
improved, paired end reads being a good example.  Many of the platforms are 
capable of generating paired end reads, working from either side of the 
fragments, thus enabling longer strands to be processed and increasing sequence 
quality. 
1.4 Mycoplasma Gene Sequencing 
In 1995 the second bacterial whole genome, and the first of the mycoplasma 
genomes, M. genitalium, was published (Fraser et al., 1995).  M. genitalium, a 
pathogen of the human genital tract, was identified as the smallest living 
genome at that time, which made it the focus of researchers aiming to create a 
synthetic genome (Gibson et al., 2008).  In 1996 the whole genome sequence of 
the phylogenetically close M. pneumoniae, a pathogen of the human respiratory 
tract, followed (Himmelreich et al., 1996).  Now more than 60 mycoplasma 
whole genomes or scaffolds are available on the National Centre for 
Biotechnology Information (NCBI) database.  Although initially mycoplasma 
sequencing was dominated by those species identified as human pathogens 
(Fraser et al., 1995, Himmelreich et al., 1996, Sasaki et al., 2002, Shu et al., 
2011), advancements in speed and capacity, in conjunction with reduced costs, 
has allowed growth in the sequencing of mycoplasmas of agricultural and 
veterinary significance (Liu et al., 2011, Wise et al., 2011, Brown et al., 2012). 
This has facilitated the development of molecular techniques for detecting these 
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fastidious organisms as well as producing a mine of information on their genetic 
potential. 
For the most researched species, the established primary pathogens, 
interactions with the host are well documented and have shown that despite 
their minimalist genome, mycoplasmas are capable pathogens.   Within their 
minimalist genome, mycoplasmas possess lots of repetitive non-coding sequence 
alongside genes inferring only basic biosynthetic and metabolic capabilities 
(Fraser et al., 1995, Citti and Blanchard, 2013).  However, mycoplasmas are very 
efficient in colonising and infecting their hosts.  Through the production of 
adhesins, lipoproteins and nucleases, the mycoplasmas are capable of hijacking 
biochemical products, inducing apoptosis (Into et al., 2002), degrade host cell 
DNA (Minion et al., 1993, Paddenberg et al., 1998), and even altering gene 
expression in host cells (Feng et al., 1999).  Minion et al. (1993) established that 
nuclease activity was essential for the growth and survival of mycoplasmas, 
likely providing a means of acquiring nucleic acid precursors they are unable to 
synthesise themselves.  Mycoplasmas efficiently produce metabolites such as 
reactive oxygen species and peroxide thus creating a cytotoxic environment for 
host cells (Cole et al., 1968, Pilo et al., 2005, Sun et al., 2008). 
1.5 Pathogenicity of Mycoplasmas 
Nucleases and proteases produced by the mycoplasmas provide a means of 
harvesting host DNA and proteins for their own biosynthetic pathways (Minion et 
al., 1993, Paddenberg et al., 1996, Paddenberg et al., 1998).  The inadvertent 
consequences involving depletion of host nutrients and generation of by-
products such as hydrogen peroxide lead to cytotoxicity and ultimately may 
induce apoptosis (Somerson et al., 1965, Cole et al., 1968, Paddenberg et al., 
1996, Paddenberg et al., 1998).   
Although generally considered to be extracellular parasites, several species have 
now been identified in intracellular locations (Tully and Whitcomb, 1979, 
Baseman and Tully, 1997, Sasaki et al., 2002).  As for any intracellular pathogen, 
this location affords a degree of protection from the host immune system and 
antimicrobial therapy, possibly contributing to the chronicity of mycoplasma 
infections (Tully and Whitcomb, 1979). For those species that remain 
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extracellular throughout infection, alternative methods to evade the host 
immune response have been documented. 
1.6 Susceptibility to Antimicrobial Drugs (AMD) 
Antimicrobial drugs may be classed in numerous ways – according to their 
chemical structure, mode of action or pharmacodynamic properties.  They may 
also be described as either bactericidal, eliminating infectious bacteria, 
generally through interference with cell wall or nucleic acid synthesis, or 
bacteriostatic, inhibiting growth by interfering with cell physiology or inhibiting 
protein synthesis (Sykes and Papich, 2014a).  
Ideally, most agents would have bactericidal properties; however bacteriostatic 
drugs are entirely capable of clearing infections with the aid of the host immune 
system.  It must also be understood that distinguishing these two distinct groups 
is difficult in some cases, with some bacteriostatic agents demonstrating 
bactericidal properties at sufficiently high concentrations.  Furthermore, the 
categorisation of whether an AMD is bacteriostatic or bactericidal may vary 
according to the target organism, the host, and the concentration of AMD 
available at the site of infection (Sykes and Papich, 2014b).   
1.7 Anti-Mycoplasma Agents 
1.7.1 Tetracyclines 
Tetracyclines take their name from their four hydrocarbon ring chemical 
structure and were  derived originally from the Streptomycetes (Cotton, 2015).  
The tetracyclines reversibly bind to the 30S ribosomal subunit thus preventing 
new amino acids being added to developing chains and stalling protein synthesis 
(Neu and Gootz, 1996, Schwarz and Chaslus-Dancla, 2001). Defined as 
bacteriostatic and demonstrating broad spectrum activity, the more recently 
developed tetracyclines such as doxycycline, demonstrate a higher efficacy 
against susceptible bacteria, even when compared to earlier generations of 
tertracyclines (Morley et al., 2005).   
1.7.2 Macrolides 
Macrolides take their name from the macrolide ring structure common to these 
chemicals, also produced by Streptomycetes (Bauman, 2011).  The structure may 
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be altered by the attachment of various deoxy sugar components (Berg et al., 
2007).  These changes in structural chemistry provide a range of macrolide drugs 
with differing properties.  Common to all macrolides however, is their mode of 
action.  Macrolides are protein synthesis inhibitors which bind to the 50S 
ribosomal subunit, inhibiting the formation of new peptide chains.   Typically, 
macrolides are bacteriostatic however they have been proven to have 
bactericidal properties when the intracellular concentration is sufficiently high 
(Wermuth, 2011).  These AMDs, such as azithromycin and erythromycin, are 
broad spectrum antibiotics, active against both Gram-positive and Gram-
negative bacteria (Neu and Gootz, 1996).  Erythromycin, discovered in 1949 was 
the original macrolide (Wermuth, 2011), with many derivatives such as 
azithromycin and clarithromycin now in use. 
1.7.3 Fluoroquinolones 
Fluoroquinolones also take their name from their chemical structure – a 
quinoline ring with a fluorine atom attached.  These drugs are entirely synthetic, 
derived from the original quinolone; nalidixic acid (Emmerson and Jones, 2003).  
Since then, numerous quinolone drugs have been developed, and a hierarchy of 
first (nalidixic acid), second (ciprofloxacin) and third generation (pradofloxacin) 
compounds are available (Andersson and MacGowan, 2003).  Newer drugs such as 
pradofloxacin are most effective;  these broad spectrum AMDs have provided a 
relatively new and effective line of defence, and are predominantly bactericidal 
(Neu and Gootz, 1996).  Fluoroquinolones interfere with DNA and protein 
synthesis by binding to topoisomerase II (DNA Gyrase) or topoisomerase IV, 
responsible for untangling and packaging DNA.  These enzymes are critical to 
DNA replication, thus their inhibition leads to cell death.  The drugs are able to 
cross freely into eukaryotic cells via porins to attain high intracellular 
concentrations which are ideal for single dose administration (Sykes and Papich, 
2014b). 
1.8 Antimicrobial Resistance (AMR) 
Since their discovery early in the 20th century, AMDs have been used routinely in 
the prevention, treatment and control of infection in humans, animals and 
plants but also within food producing animals to promote growth (Schwarz and 
Chaslus-Dancla, 2001, CDC, 2014). Their efficiency in preventing and clearing 
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infections, compounded with the development of vaccines, allowed the near 
elimination of previously fatal infectious diseases, such as tuberculosis and 
syphilis, from the developed world (CDC, 1999). However, less than 100 years 
since the discovery of penicillin, it is apparent that there has been a degree of 
misuse, resulting in the decreasing susceptibility of microbes to AMDs. 
AMR may be an inherent property of an organism – e.g. mycoplasmas lack a cell 
wall and therefore cannot be targeted by beta-lactams, or an acquired property 
e.g. tetracyclines for which more than forty microbial gene mutations have been 
identified which result in a resistant phenotype (van Hoek et al., 2011). 
Microbes are evolving more rapidly than their hosts; however it is crucial to keep 
in mind that heterogeneity exists in all microbial populations, thus the 
prevalence of resistance is not uniform.  Chemotherapy then does not induce the 
mutation conferring resistance, rather, it selects for it, thus allowing the 
flourishing and development of populations resistant AMDs (Neu and Gootz, 
1996, Schwarz and Chaslus-Dancla, 2001, van Hoek et al., 2011).  It should also 
be noted that host commensals, as well as the target organism are exposed to 
AMDs (Sykes and Papich, 2014a), causing selection of resistant commensal 
bacteria and possibly altering the normal flora (Neu and Gootz, 1996). This in 
turn creates a reservoir of resistance genes within the host microbiome, thus 
creating an environment ripe for horizontal gene transfer between any microbes 
within that host (Morley et al., 2005) or any other recipient which the microbe 
may be transmitted to, further fuelling the development of AMD resistance.  This 
has resulted in acquired resistance mechanisms being accountable for most 
resistance problems in modern medicine (Schwarz and Chaslus-Dancla, 2001). 
Various mechanisms have been identified which confer resistance to AMDs, and 
these will be discussed further below, specifically with regard to resistance to 
anti-mycoplasma agents.  It should be noted that these resistance mechanisms 
are not exclusive, and in many bacteria the simultaneous possession of multiple 
resistance mechanisms is not uncommon (Neu and Gootz, 1996, van Hoek et al., 
2011) and may result in multi-drug resistant strains of bacteria as has been seen 
in Mycobacterium tuberculosis.  
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Many strategies and guidelines have been made available, with the aim of 
reducing or slowing the development of antimicrobial resistance (Edwards et al., 
2004, Morley et al., 2005, Weese, 2006, CDC, 2014, Sykes and Papich, 2014a, 
Sykes and Papich, 2014b).  All guidelines acknowledge that empirical treatment 
must be minimised, and that use of AMDs must be lessened in order to protect 
their efficacy.  In order to achieve this, it is recommended that an evidence-
based approach to AMD employment is required. 
A case study published in 2001 also emphasises this need, reporting on 3 cases of 
human mycoplasma infections, initially treated empirically.  Each of the three 
cases demonstrated resistance to combinations of conventional mycoplasma 
therapies, requiring the employment of a pleuromutilin drug, at the time not 
approved for human administration (Heilmann et al., 2001), to effectively treat 
the infections.  It was noted that in 2 of the three cases, facilities for 
antimicrobial susceptibility testing were unavailable and for the third case, no 
susceptibility testing was done until the patient was found to be unresponsive to 
traditional therapy.  The outcome was that two of the patients had significant 
hospital stays and the other patient died (Heilmann et al., 2001).  Had 
susceptibility testing been available and utilised in the first instance, the 
appropriate antimicrobial therapy could have been employed much earlier, 
potentially improving patient prognosis. 
1.9 Antimicrobial Resistance in Mycoplasmas 
Currently, in the treatment of confirmed M. felis infection, doxycycline is 
recommended as the first line of treatment (E Graham, personal 
communication).  Although numerous studies have investigated the antimicrobial 
susceptibility of animal mycoplasmas (Taylor-Robinson and Bébéar, 1997, Vicca 
et al., 2004, Man et al., 2012), only one study has documented results for M. 
felis specifically (Kibeida, 2010).  Using six field isolates, obtained from nasal 
flushes, and a range of AMDs including doxycycline, enrofloxacin and 
erythromycin, the MIC90 values were recorded as 0.25 µg/mL, 0.031 µg/mL and 
128 µg/mL respectively.  Given the recommendations on prudent use of 
fluoroquinolones in veterinary medicine (Edwards et al., 2004, Weese, 2006), 
these data support doxycycline as a first line treatment. 
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The low susceptibility to erythromycin among M. felis isolates, demonstrated by 
Kibeida (2010) is echoed in other studies where macrolides are repeatedly least 
effective (Taylor-Robinson and Bébéar, 1997, Vicca et al., 2004, Man et al., 
2012).  One interesting study focussed on the emergence of resistance in vitro 
for mycoplasma strains M. gallisepticum, M. iowae and M. synoviae using 
selective culture and performing assays after each passage.  This demonstrated 
that the most rapid emergence of resistance was to the macrolide erythromycin 
in all of the species tested (Gautier-Bouchardon et al., 2002).  Resistance to 
oxytetracycline could not be produced in M. gallisepticum or M. synoviae after 
10 culture passages and resistance to enrofloxacin was slow in all tested 
isolates. 
Of other studies reviewed, one recorded decreased susceptibility to enrofloxacin 
in 59% (MIC range1 to >16 µg/mL) of M. synoviae field isolates tested 
(Lysnyansky et al., 2013) with other mycoplasmas; M. hyopneumoniae, M. bovis 
and M. synoviae giving MIC90 values of 0.5 µg/mL, 4 µg/mL and 8 µg/mL for 
respectively (Vicca et al., 2004, Man et al., 2012, Lysnyansky et al., 2013).  Man 
et al. (2012) also documented decreased susceptibility of M. bovis to 
doxycycline (MIC90 of 32 µg/mL). 
These studies indicate that AMR is emerging within the mycoplasmas, although 
susceptibilities appear to be inconsistent across species, they do seem to 
correlate with the level of exposure to specific AMDs, particularly within food 
production animals (Schwarz and Chaslus-Dancla, 2001, Morley et al., 2005, CDC, 
2014, Wegener, 2012).  Although multi-drug resistance only seems to be notable 
in M. bovis, the variance of susceptibilities between species is indicative that 
the emergence of resistance within any mycoplasma species is probable rather 
than possible when challenged by chemotherapeutic selection pressures. 
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1.10 Mechanisms of Resistance 
The mycoplasmas are inherently resistant to all beta-lactam antimicrobials due 
to their lack of cell wall and therefore peptidoglycan target.  For mycoplasma 
genomes which have been sequenced in their entirety, only minimal DNA repair 
genes have been documented (Rocha and Blanchard, 2002), this likely 
contributes to the high mutation rates which characterise mycoplasmas (Razin et 
al., 1998).  This mutator phenotype created by reduced DNA repair mechanisms 
and increased mutation frequency confers an increased likelihood of acquired 
resistance.  Acquisition of new genes has also been documented in mycoplasmas.   
The main mechanisms of AMD resistance are summarised below: 
 Production of enzymes 
 Target modification 
 Drug exclusion 
 Ribosomal protection proteins 
The production of enzymes such as esterases, allow the addition of new 
molecules to the drugs chemical structure, thus changing structure, function and 
action of the drug.  This mechanism has been implicated in AMR to macrolides 
and also tetracyclines (Berg et al., 2007, Bauman, 2011).   
Modifications such as the methylation of adenine nucleotide components of the 
50S ribosomal subunit may lead to resistance to macrolides by decreasing the 
binding affinity of the target receptor (Neu and Gootz, 1996).  Susceptibility to 
fluoroquinolones may also be affected by target modification; commonly 
chromosomal mutations which result in a conformational change in the A or B 
subunit of DNA gyrase, have been identified however may also be a result of 
increased drug efflux or reduced bacterial permeability or a combination of both 
(Neu and Gootz, 1996, Sykes and Papich, 2014b). 
Active efflux, or energy dependent efflux, of AMDs also decreases the 
antimicrobial action of drugs such as macrolides which may be actively exported 
from cells.  Tetracyclines are particularly vulnerable to this mechanism, and the 
tetK gene has been identified as mediating increased drug efflux within bacteria 
such as Staphylococcus aureus and Enterococcus faecalis, making them resistant 
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to all tetracyclines (van Hoek et al., 2011).  Alternative mechanisms for drug 
exclusion involve the change in permeability of the bacterial cell wall, limiting 
the access of AMDs to target sites.  Mutations within porins of the cell wall have 
also been identified as enabling resistance to drugs including macrolides, 
tetracyclines and fluoroquinolones, by reducing permeability and ultimately 
preventing AMDs reaching their target receptor. 
Ribosomal protection proteins have been implicated in resistance to 
tetracyclines and macrolides.  Within mycoplasmas, the predominant 
tetracycline resistance gene has been identified as tetM (Pich et al., 2006, 
Mardassi et al., 2012) which has been characterised as encoding a cytoplasmic 
protein capable of dislodging any tetracycline bound to its target site on the 
ribosome.  
1.11 Minimum Inhibitory Concentration Testing 
Susceptibility testing, or minimum inhibitory concentration (MIC) testing, is an 
effective tool used routinely in many laboratories to establish which AMDs are 
effective against which microbes.  Its employment provides an in vitro 
measurement of how susceptible a microbe is to a particular drug by 
demonstrating the lowest concentration required to inhibit growth of a target 
organism (Andrews, 2001, Wiegand et al., 2008).  The procedure employs one 
antimicrobial agent, at progressively lower concentrations, along with a 
standardised inoculum of the organism of interest, incubated for a defined 
period of time. Growth may be visualised by turbidity, a zone of inhibition or a 
colour change (using a pH indicator dye), indicating the concentration of the 
antimicrobial agent which prevents growth and reproduction of the organism. 
The MIC value is between the concentration of antimicrobial in which the last 
growth is observed, and the next concentration, in which no growth is visible.  
This is of relevance whilst evaluating new antimicrobial agents but also in 
assessing antimicrobial resistance, and identifying if the resistance is inherent or 
acquired, through application of established breakpoints (Wiegand et al., 2008). 
Well-standardised methods are essential in MIC testing as any variance in 
inoculum or antimicrobial concentration, pH, temperature, media composition 
or incubation period may result in significant variance in MIC values (European 
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Committee for Antimicrobial Susceptibility Testing of the European Society of 
Clinical and Infectious, 2003, Wiegand et al., 2008).  It is also important to note 
that this test does not reflect the bactericidal effect of drugs or chemicals, with 
further culture being required to establish whether the organisms have been 
eliminated or if the original inoculum is still present but unable to grow 
(Andrews, 2001). 
Depending upon the facilities of the testing laboratory and the target organism, 
various methods of MIC testing may be employed; agar dilution, agar diffusion or 
broth (micro) dilution.   
1.12 MIC Testing of Mycoplasmas 
Liquid dilutions in particular are preferable for mycoplasmas, which are slow 
growing.  Liquid culture allows growth dependent changes to be observed, such 
as those induced by metabolites.  Liquid culture has also proven to be more 
sensitive for slow growing organisms (WHO, 2014) and in slowing degradation of 
drugs (Heifets, 1991), this is particularly relevant within MIC testing of 
mycoplasmas as effective drugs, such as the tetracyclines, are considered to be 
unstable and degrade quickly (Wiegand et al., 2008).  MIC testing in liquid 
culture within mycoplasma diagnostics is also beneficial as there is no 
requirement for a supplement to the media, as there is for solid mycoplasma 
media, thus reducing variances in media composition and improving 
standardisation.  The employment of liquid microdilution also reduces the 
volume of reagents required and, as many antimicrobial agents may be set up on 
one plate, allows and easy and direct comparison of the antimicrobial activity of 
multiple agents in one test. 
1.13 Project Summary 
Currently, screening for M. felis is part of the routine diagnostic service at the 
Glasgow University Veterinary Diagnostic Service, and when isolated, whether 
from a respiratory or conjunctival sample, the infected cat is treated with 
antimicrobials.  To date, only sparse antimicrobial breakpoints are available for 
mycoplasmas, with none available for M. felis specifically.  Evidence suggests 
that M. felis is likely an ocular pathogen in cats, however when isolated from 
cats with respiratory tract disease, its pathogenic role is still unclear.   
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The first objective of this project is to examine antimicrobial susceptibility 
phenotypes amongst ocular clinical isolates and an M. felis reference strain in 
order to identify any emerging resistance and determine the most effective in 
vitro antimicrobials.  
Secondly, within this project, the DNA sequence of a selection of clinical isolates 
and the reference strain will be obtained using Next Generation Sequencing 
Technology.  Mycoplasmas identified as pathogens in humans and animals will be 
used as reference genomes in order to search for known markers of virulence in 
mycoplasmas and allow identification of any antimicrobial resistance genes.   
In conclusion, this project aims to correlate observed phenotype with obtained 
genotype.  This will allow evidence-based employment of antimicrobials and 
novel exploration of the M. felis genome and its potential for virulence which in 
future may be further investigated in cell infection studies. 
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Chapter II 
Phenotypic Characterisation of Mycoplasma felis Clinical Isolates 
2.1 Introduction 
Although some studies have attempted to explore the pathogenicity of M. felis, 
the results have not been consistent or reproducible (Campbell et al., 1973, 
Shewen et al., 1980, Haesebrouck et al., 1991b, Wood et al., 1997). 
This project aims to re-examine the pathogenic potential of M. felis, and 
establish whether virulence can be correlated with phenotypic markers.  This 
chapter will record the phenotypic properties of M. felis clinical isolates 
including antibiograms and pattern of haemolysis. Examination of these markers 
will also provide immediate information regarding variance among different 
isolates and possibly identify emerging antimicrobial resistance (AMR).   
These points are relevant in a clinical setting, where the straightforward 
identification of a phenotype of virulence will allow evidence-based 
recommendations to be made to veterinary practitioners regarding M. felis 
infection; firstly, is treatment required, and secondly, what is the most 
appropriate treatment. 
2.1.2 Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing using the MIC method is an effective tool 
used routinely in diagnostic laboratories to establish which AMDs are effective 
against which microbes.  Liquid microdilutions are preferable for slow growing 
organisms such as mycoplasmas and, when set up on a 96-well microtitre plate, 
allows easy visualisation of results and comparison of antimicrobial 
susceptibilities.  Within the Veterinary Diagnostic Services (VDS) laboratory of 
the University of Glasgow, antimicrobial susceptibility testing (discs) is utilised 
in routine practice for all samples received which are suspected to contain 
bacterial pathogens.  However, susceptibility testing of mycoplasmas is not in 
place and due to their slow growing and fastidious nature, would be difficult to 
implement.   
The method used in this study to establish MIC values of mycoplasmas in liquid 
culture will be based on a prior publication (Hannan, 2000).The liquid broth used 
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employs phenol red as a pH indicator – in the presence of M. felis, glucose is 
metabolised, producing acidic metabolites and causing the pH indicator to pale 
from red to yellow, indicative of growth. This colour change is used to identify 
the MIC value following 48-hour incubation under microaerophilic conditions. 
MIC values for seven antimicrobials against clinical M. felis isolates will be 
determined; six of these have expected activity against M. felis: enrofloxacin, 
pradofloxacin, oxytetracycline, doxycycline, erythromycin and azithromycin. 
The β-lactams are acknowledged to be bactericidal.  By binding to and inhibiting 
penicillin binding proteins required for synthesis of the peptidoglycan layer of 
the bacterial cell wall, these drugs ultimately result in rupture of the bacterial 
cell wall (Sykes and Papich, 2014b).  Due to their lack of cell wall, mycoplasmas 
are inherently resistant to β-lactam antibiotics however for the purpose of this 
project; the β-lactam ampicillin (AMP) was employed as a control. 
Antimicrobial susceptibility testing allows the evaluation of new antimicrobials 
and also the assessment of antimicrobial resistance through the application of 
established breakpoints (Wiegand et al., 2008).  Since acquired resistance has 
been demonstrated in numerous mycoplasmas (Roberts et al., 1985, Heilmann et 
al., 2001, Vicca et al., 2004, Pich et al., 2006, Man et al., 2012, Lysnyansky et 
al., 2013, Gautier-Bouchardon et al., 2014), susceptibility testing to aid directed 
therapy is increasingly important.   
In 2011, the Clinical Laboratory Standards Institute (CLSI) published the first 
antimicrobial breakpoints for mycoplasmas, but for only three mycoplasma 
species, all implicated in human infection. To date, no mycoplasma breakpoints 
are available from the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST).  The lack of defined breakpoints for animal mycoplasmas 
makes it challenging to provide a laboratory result that can confidently drive 
therapy. Throughout the literature, in vitro susceptibilities for mycoplasmas 
have been reported with various interpretations of MIC values (Whithear et al., 
1983, Roberts et al., 1985, Taylor-Robinson and Bébéar, 1997, To et al., 2010, 
Schultz et al., 2012, Gautier-Bouchardon et al., 2014) therefore making it 
difficult to define any emerging resistance not only within this study, but in 
animal mycoplasmas in general. 
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2.1.3 Haemolysis  
Haemolytic activity represents the lysis of erythrocytes by a haemolysin, and 
may be observed during culture of an organism on blood agar.  The colour of the 
agar beneath colonies is indicative of the type of haemolysis – with green being 
associated with α-haemolysis, a partial lysis of erythrocytes, and clearing of the 
agar beneath and surrounding the colonies, being indicative of β-haemolysis, 
complete lysis of erythrocytes (Bauman, 2011).  Cole et al. (1967) first 
characterised M. felis and described varying degrees of haemolytic activity on 
sheep, guinea pig, chicken, duck and horse blood agar.  Although haemolytic 
activity is a useful tool in aiding the identification of organisms in culture in vivo 
haemolysis is unusual unless there is an underlying condition.   
Research of haemolysin production in opportunistic pathogens such as 
Staphylococcus aureus and Escherichia coli has established that for those 
organisms possessing haemolysin markers, other virulence markers such as 
cytotoxic necrotising factor, were also identified.  Thus, these organisms were 
determined to have higher potential virulence in vivo (Hughes et al., 1983, 
Cherifi et al., 1990, Cotar et al., 2010). 
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2.2 Materials and Methods 
2.2.1 Mycoplasma Isolates 
Ocular swabs received by the University of Glasgow’s Veterinary Diagnostics 
Service (VDS), for routine diagnostic testing were cultured in mycoplasma Liquid 
Broth (LB) and mycoplasma Agar (AG) (Mycoplasma Experience, Reigate, UK) as 
described below.  Culture positive results were verified by M. felis species-
specific real-time PCR, with original isolates frozen in cryovials (Thermo Fisher 
Scientific, Hemel Hempstead, UK) at -70°C.  Mycoplasma felis strain 10160 (Cole 
et al., 1967) from the National Collection of Type Cultures (NCTC, Salisbury, UK) 
was used as a control strain throughout this study. Seventy-eight clinical isolates 
of M. felis, received between 2007 and 2014, from throughout the UK and 
Scandinavia, along with M. felis strain D8 (Wood et al., 1997) were available for 
this study.  
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Figure 2.1 Origin of Mycoplasma Isolates Used in this Study 
 
Red pointers mark the origin of Mycoplasmas isolates used within this study.  As 
demonstrated in the map, a variety of UK areas are represented.  Two isolates 
from Scandinavia were also cultured for use (not shown). 
Table 2.1 Details of Mycoplasma felis isolates studied during this project 
Isolate ref 
Date 
Rcvd 
Origin Age Area Presentation 
Multicat 
Household 
10160 1967 Cole et al. 1967 - - - - 
D8 1997 Wood et al. 1997 - - - - 
3 Apr-08 Ocular Swab 7 m BT39 ocular discharge - 
4 Dec-09 
Conjunctival 
Swab 
- PA34 conjunctivitis - 
5 Apr-08 
Conjunctival 
Swab 
11 m G71 r/c epiphora, purulent conjunctivitis, sneezing - 
6 May-08 
Conjunctival 
Swab 
4 y EH54 r/c discharge from eyes - 
7 Nov-08 
Conjunctival 
Swab 
1 y M41 Severe gingivitis and conj. - 
8 Nov-13 Eye swab 1 m CA8 - - 
9 Dec-13 Eye swab - M26 - - 
10 Dec-13 
Conjunctival 
Swab 
3 m HX1 Conj with mucopurulent discharge Y 
11 Apr-03 Corneal Swab - BN1 Corneal ulcer Y 
12 Jul-08 
Conjunctival 
Swab 
9 y 7 m G61 ulcer, leukosis, weight loss, anorexia - 
13 Sep-14 
Conjunctival 
Swab 
16 y 11 
m 
EH54 corneal ulcer - 
14 Aug-14 
Conjunctival 
Swab 
11 m SE9 conj, green discharge, inflammed - 
15 Jun-08 
Conjunctival 
Swab 
- NW9 - - 
16 Oct-13 Conjunctival 14 y CM12 Ulcer on eye N 
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Isolate ref 
Date 
Rcvd 
Origin Age Area Presentation 
Multicat 
Household 
Swab 
17 Oct-13 Eye swab 2 m LS8 Conj. And chemosis Y 
18 May-08 
Conjunctival 
Swab 
1 y 8 m CM7 purulent conjunctivitis - 
19 Jul-08 
Conjunctival 
Swab 
- NP25 conjunctivitis - 
20 Aug-08 
Conjunctival 
Swab 
1 y 2 m BB1 bilat conj ongoing. General malaise  - 
21 Feb-14 
Conjunctival 
Swab 
13 y SK8 - - 
22 Apr-03 
Conjunctival 
Swab 
8 m RM2 Chronic conj.  Recent resp symptoms Y 
23 May-08 
Conjunctival 
Swab 
12 w SA2 bilar conj, nasal discharge.  - 
24 May-08 
Conjunctival 
Swab 
- NO epiphora - 
25 May-08 
Conjunctival 
Swab 
7 m NW10 bilat severe conj with chemosis - 
26 May-08 
Conjunctival 
Swab 
3 y 8 m NE29 epiphor, severe conjunctivitis, worse L eye - 
27 May-08 
Conjunctival 
Swab 
1 y SE4 cat flu; had kittens 2 died pneumonia/pleurisy - 
28 Jun-08 
Conjunctival 
Swab 
8 y 7 m G61 acute unilat conj - 
29 Jun-08 
Conjunctival 
Swab 
3 y 6 m DY8 r/c sneeze, conj. Unilat ulcer - 
30 Jun-08 Conjunctival 9 m HP23 bilateral severe conjunctivitis - 
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Isolate ref 
Date 
Rcvd 
Origin Age Area Presentation 
Multicat 
Household 
Swab 
31 May-14 
Conjunctival 
Swab 
11 m B62 - - 
32 Sep-08 
Conjunctival 
Swab 
3 m SP8 Conj. In group of kittens Y 
33 Sep-14 
Conjunctival 
Swab 
2 m SS4 conj - 
34 Jan-13 
Conjunctival 
Swab 
5 m CM12 Conj, swollen with puss - 
35 Aug-13 
Conjunctival 
Swab 
- LE14 conj - 
36 Sep-13 
Conjunctival 
Swab 
2 m OX12 Conj, sneezing and pyrexia - 
37 Oct-13 
Conjunctival 
Swab 
3 m CV22 Recurrent conj. Y 
38 Oct-13 
Conjunctival 
Swab 
2 m TR1 Conj with discharge - 
39 Jan-14 
Conjunctival 
Swab 
1 y 8 m CV22 conj - 
40 Feb-14 
Conjunctival 
Swab 
4 y 8 m RG9 Severe conj, deep ulcer, blepharospasm - 
41 Apr-14 
Conjunctival 
Swab 
17 y SG8 conj - 
42 Jan-14 
Conjunctival 
Swab 
12 y 3 
m 
G61 respiratory symptoms - 
43 May-14 
Conjunctival 
Swab 
11 m M26 Chronic conj. - 
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Isolate ref 
Date 
Rcvd 
Origin Age Area Presentation 
Multicat 
Household 
44 May-14 
Conjunctival 
Swab 
1 m NE5 conj - 
45 Jul-14 
Conjunctival 
Swab 
2 y PR3 severe conj - 
46 Jul-14 
Conjunctival 
Swab 
3 m NE7 conj - 
47 Feb-14 
Conjunctival 
Swab 
8 y DK conj and persistent sneezing - 
48 Nov-14 
Conjunctival 
Swab 
14 y 10 
m 
TW1 - - 
NE01 Mar-08 
Conjunctival 
Swab 
9 w TN17 bilat ulcerative KC, occasional sneezing - 
NE10 Jan-13 
Conjunctival 
Swab 
1 y 5 m RM15 Severe conj. - 
NE11 Mar-13 
Conjunctival 
Swab 
11 m WS13 Long term ocular discharge with conj and sneezing - 
NE12 Sep-13 
Conjunctival 
Swab 
6 m HP15 Chronic conj - 
NE13 Oct-13 
Conjunctival 
Swab 
20 y 5 
m 
SS17 Chronic, recurring conj - 
NE14 Nov-13 Eye swab 7 m KT12 Chronic conj - 
NE15 Jan-14 
Conjunctival 
Swab 
5 m BH11 Blepharitis, epiphora, mucoid discharge - 
NE16 Jan-14 
Conjunctival 
Swab 
7 m CV5 conj - 
NE17 Mar-14 
Conjunctival 
Swab 
2 m SS4 - - 
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Isolate ref 
Date 
Rcvd 
Origin Age Area Presentation 
Multicat 
Household 
NE18 Apr-14 Eye swab 9 m GU1 previous mycoplasma infection - 
NE19 May-14 
Conjunctival 
Swab 
8 m HD5 corneal ulcer, FCV in household - 
NE02 Nov-08 
Conjunctival 
Swab 
17 y GU21 Repeated URTI - 
NE20 Jun-14 
Conjunctival 
Swab 
1 y 1 m M44 conj - 
NE21 Aug-14 
Conjunctival 
Swab 
3 m CH43 persistent sneezing - 
NE22 Aug-14 
Conjunctival 
Swab 
13 y 10 
m 
RG9 watery mucopurulent discharge - 
NE23 Sep-14 
Conjunctival 
Swab 
- M16 conj - 
NE24 Sep-14 
Conjunctival 
Swab 
5 m DK - - 
NE25 Oct-14 
Conjunctival 
Swab 
17 y AL4 persistent sneezing - 
NE26 Oct-14 
Conjunctival 
Swab 
4 m PO16 persistent sneezing - 
NE03 Mar-13 
Conjunctival 
Swab 
6 m DN22 - - 
NE04 Mar-14 
Conjunctival 
Swab 
7 y 3 m TW1 lymphoid rhinitis - 
NE05 Apr-10 Eye swab 1 m SM4 recurrent eye problems Y 
NE06 Aug-08 
Conjunctival 
Swab 
1 y 8m B13 pyrexia, sneezing, red and runny eye - 
NE07 May-08 Conjunctival 2 m ME5 bilat conj and nasal discharge - 
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Isolate ref 
Date 
Rcvd 
Origin Age Area Presentation 
Multicat 
Household 
Swab 
NE08 May-08 
Conjunctival 
Swab 
13 w CT14 sneezing, mild ocular discharge, mild nasal discharge post vacc - 
NE09 Oct-08 
Conjunctival 
Swab 
3 m MK7 Flu, occular signs and sneezing - 
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2.2.2 Mycoplasma Media 
Mycoplasma Agar (AG): 
The AG was prepared according to manufacturer’s instructions (Mycoplasma 
Experience).Briefly, AG stored at 4°C, was melted in a boiling water bath then 
allowed to cool on the bench for 5 minutes.  The mycoplasma supplement, 
stored at -20°C, was thawed in a 37°C water bath before transfer to a 56°C 
water bath with the cooled AG.  The supplement and agar were kept in the 56°C 
water bath for approximately 20 minutes to allow temperatures to equilibrate.  
The mycoplasma supplement was poured into the agar and gently inverted to 
mix, avoiding bubbles, before being poured into 35 x 10 mm petri dishes (Falcon, 
Corning, USA) and allowed to set (approx. 30 minutes) before being refrigerated 
at 4°C for up to 2 weeks. 
Mycoplasma Liquid Broth (LB): 
The LB was prepared according to manufacturer’s instructions (Mycoplasma 
Experience).  Stored at -70°C, the LB was thawed in a 37°C water bath (approx. 
1 hour). The media was then aliquoted, under aseptic conditions, in a laminar 
flow hood, in 2 mL volumes, into Vacuettes® (Greiner Bio-One, Kremsmuenster, 
Austria).  Each prepared vacuette was stored at -20°C and thawed at room 
temperature as required.  All prepared vacuettes were used within 2 weeks of 
preparation.  This LB contains the pH indicator phenol red.  The standard pH of 
the LB was found to be pH 7.2. 
Preparation of Stock Mycoplasma Cultures 
Each frozen isolate was thawed at room temperature and then inoculated into 
LB or AG as described below.  The AG was streaked with a colony from the 
original M. felis clinical isolate or inoculated with 100 µL original liquid culture 
and allowed to dry before incubation. The LB was inoculated with 200 µL original 
liquid culture isolate, or an agar block known to contain colonies.  The 
inoculated media were placed in a microaerophilic incubator (DW Scientific, 
West Yorkshire, UK) at 37°C under microaerophilic conditions (5% O2, 5% CO2, 5% 
H2, 85% N2), for 48 hours or until growth was observed.  Liquid broth showing 
growth, indicated by the pH indicator within the media, was briefly vortexed 
then aliquoted into 1.5 mL cryovials (Thermo Fisher Scientific) in 200 µL volumes 
for storage.  Visible colonies were cut out from agar in blocks using a sterile 
scalpel and placed in cryovials (Thermo Fisher Scientific) for storage at -
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70°C.Non-inoculated and therefore negative LB and AG controls were included 
for each batch of isolates being cultured to ensure no contamination. 
2.2.3 Viable Cell Count 
In order to ensure a standard concentration of inoculum for each MIC test and 
avoid spurious results, a viable cell count (VCC) was performed for the M. felis 
reference strain 10160, D8 and each M. felis clinical isolate according to 
previously published protocols (Hannan, 2000). 
The VCC of strain 10160 was determined, in triplicate, for lag (freshly thawed, 
diluted 1:10 in LB and immediately tested for viability), lag +2 (thawed, diluted 
1:10 in LB, and incubated for 2 hours before viability testing), and logarithmic 
growth cultures (thawed, diluted 1:5 and incubated for 48 hours prior to viability 
testing) in order to determine if there were identifiable differences in viability 
between growth phases and establish repeatability.  The minimal variance in 
these results allowed the employment of lag +2 testing of clinical isolates which 
substantially reduced the time required for testing.   
Isolates were tested in batches of eight, allowing one row per isolate on a 96-
well plate.  Ten-fold dilutions (100 to 10-9) of each culture were prepared in 1.5 
µL microfuge tubes.  The lowest concentration (10-9) of each isolate was added 
to well 8 of the allocated row.  From there, wells were inoculated from lowest 
to highest concentration, until well 1 of each row which held the highest 
concentration (10-2).  A sterility control (200 µL LB) was also added to well G11 
to ensure sterility of the media.  The 96-well plate was then sealed and 
incubated in a microaerophilic incubator, being checked for growth after 48 
hours and again after 7 days.  Growth across dilutions allowed colour changing 
units (ccu) to be calculated, which correlates well with colony forming units 
(cfu) traditionally used in enumerating bacterial cells (Stemke and Robertson, 
1982).   
A minimum concentration of 104ccu/mL mycoplasma cultures was required for 
MIC testing; therefore any isolates with a viable count lower than this were 
concentrated by either adding a higher volume of inoculum to a lower volume of 
LB or by inoculating AG and incubating until colonies were visible and removing 
agar plugs into LB for further incubation.  The AG plugs seemed to be most 
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effective in increasing concentration and so this was employed whenever 
possible. 
2.2.4 Antimicrobial Preparation 
Antimicrobials as listed below were purchased in powder form and stored 
according to manufacturer’s instructions until required (Table 2.2).  
Antimicrobial solutions were prepared in 2mL volumes.  The calculation 
described by Hannan (2000) below, was used to generate a correction factor, 
taking account of purity and salt content, which in turn was used to calculate 
the volume of solvent required to ensure a starting concentration of 1000µg/mL. 
(mw of active base / total mw) x (purity / 100) = correction factor 
Correction factor x weight of antimicrobial powder being used = volume of 
solvent required 
Azithromycin, erythromycin and enrofloxacin were dissolved in 100% ethanol, 
with all other antimicrobials being dissolved in deionised water (dH2O).  
Solutions were adjusted to a pH of between 7.1-7.4 to ensure that only colour 
changes reflective of growth would be observed in LB. The solutions were then 
filtered, using a 10mL syringe (BD Plastipak, Madrid, Spain, and 0.20 µM pore 
filter (Sartorius, Surrey, UK) to ensure sterility.  A concentration range (64 
µg/mL to 0.03 µg/mL) was prepared for each antimicrobial solution by making 
two-fold dilutions in LB as described by Hannan (2000). Fresh solutions of 
azithromycin, erythromycin, doxycycline and oxytetracycline were prepared for 
each assay as previous publications noted them to be unstable (Hannan, 2000, 
Andrews, 2001, Wiegand et al., 2008).  Stock solutions of ampicillin were stored 
in 200 µL aliquots at -20°C for up to 4 weeks (Hannan, 2000, Andrews, 2001); 
stock solution of pradofloxacin was stored in a glass vial, in the dark, at room 
temperature for up to 2 weeks (Wiegand et al., 2008); stock solution of 
enrofloxacin was stored in a glass vial wrapped in foil, in the dark, at room 
temperature.  A previous publication found enrofloxacin to be stable for up to 56 
days (Metry et al., 2012), however due to prohibitive costs; a 5 mL stock solution 
was retained for 5 months.  The pH was monitored weekly, with adjustments 
being made as required.  Efficacy was monitored using the MIC results of the 
reference isolate (NCTC 10160).
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Table 2.2 Properties of Antimicrobial Drugs Used in MIC Testing 
Antimicrobial Manufacturer Solvent Storage Duration of Stability 
Ampicillina Sigma-Aldrich Co. Ltd, UK dH2Od -20°C 30 days 
Azithromycin EDQM, France 100% Ethanol Dark, RTb unstable 
Doxycycline Fischer BioReagents, UK dH2O Dark, RT unstable 
Enrofloxacin EDQM, France 100% Ethanol Dark, RT 5 monthsc 
Erythromycin EDQM, France 100% Ethanol Dark, RT unstable 
Oxytetracycline EDQM, France dH2O Dark, RT unstable 
Pradofloxacin 
Bayer Healthcare AG, 
Germany 
dH2O Dark, RT 14 days 
 
a ampicillin was included in the study as a negative control 
b RT: room temperature 
c enrofloxacin was found to be stable after 5 months 
d distilled water 
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2.2.5 Minimum Inhibitory Concentration (MIC) Testing 
Minimum inhibitory concentration testing was performed, as described by 
Hannan (2000).  Isolates were tested in batches of four, together with the 
control strain 10160. To allow for preparation of five MIC plates, volume 
modifications to the original protocol were made as follows; 1200 µL of the first 
antimicrobial dilution (128 µg/mL) were required therefore 153.6 µL of each 
prepared antimicrobial solution was added to 1046.4 µL LB. Doubling dilutions 
were obtained using 600 µL antimicrobial dilutions into 600 µL fresh LB until a 
final concentration of 0.0625 µL/mL was achieved for each antimicrobial with 
the exception of ampicillin which was diluted to 0.5 µg/mL only.  These 
antimicrobial dilutions were added to sterile 96-well plates in 100 µL volumes as 
represented in Appendix 1. 
For each isolate MIC test, 9 mL inoculum was required.  The VCC for each isolate 
was used to prepare an inoculum of 104 ccu/mL of lag +2 growth phase culture 
which was then dispensed onto the MIC plate in 100 µL volumes.   
Each 96-well plate included a VCC for the test isolate to ensure standardisation 
of the inoculum concentration.  Solvent controls were included to ensure that 
the solvents used to dissolve the antimicrobials did not inhibit growth.  An end-
point control was prepared by adjusting the LB to pH 6.8, providing a colour 
indicator for growth. A sterility control (SC) (200 µL non-inoculated LB) and a 
growth control (GC) (200 µL inoculum) were also included. Control strain 10160 
was also tested with each batch of clinical isolates to ensure consistent 
antimicrobial performance.  To ensure a pure culture of each isolate was tested, 
AG was inoculated with 100 µL inoculum. 
MIC plates were incubated in a microaerophilic incubator until the colour of the 
growth control well matched the colour in the end point control well.  In 
experiments where the VCC was out-with the recommended range of 103 to 
105ccu/mL(Hannan, 2000), the test was repeated. The AG for each isolate was 
checked at the same time as the MIC plate to ensure a pure M. felis culture. 
After all isolates had been tested, results were compared and isolates giving 
outlying results were repeat tested to ensure reproducibility. 
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2.2.6 Determination of Biostatic or Biocidal Activity 
Using the reference strain 10160, MIC testing was set up as described above. 
After 48 hours, 100 µL of culture was removed from each well showing no colour 
change, indicative of no growth, and inoculated onto AG.  This further dilution 
of antimicrobial drug should allow growth of any viable mycoplasmas.  Agar 
plates were examined after 48 hours incubation to check for growth, indicating 
the antimicrobial to be bacteriostatic or bactericidal for those showing no 
growth.  This experiment was repeated in triplicate to ensure reproducibility. 
2.2.7 Haemolysin Activity 
100 µL of each isolate was inoculated onto Sheep Blood Agar (SB) and incubated, 
as described above, for 48 hours before being examined for haemolysis.  If no 
haemolysis was visible after this time the isolates were incubated for up to 7 
days, being checked daily until haemolysis was visible. 
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2.3 Results 
2.3.1 Mycoplasma Isolates 
Sixty of the 79 retrieved isolates were successfully cultured from original clinical 
isolates.  Reference 10160 and strain D8 (Wood et al., 1997) were also cultured 
successfully, showing clear growth on AG and in LB after 48 hours incubation (Fig 
2.2 and 2.3).  
 
 
 
 
 
 
 
2.3.2 Viable Cell Count 
The comparison of results for lag, lag+2 and logarithmic growth phase viability 
counts of strain 10160 are shown in Table 2.3.  Viable cell counts of 104 ccu/mL 
or above were attained for 38 of the isolates immediately. Twenty-two isolates 
required concentration due to initial viable counts of 103ccu/mL or less. Further 
concentration yielded 14 more isolates with concentrations of 104ccu/mL or 
greater, giving a total of 51 clinical isolates, plus strain D8, with concentrations 
sufficient for MIC testing.   
 
Figure 2.3 Preparation of stock culture 
A. Freshly inoculated liquid broth 
B. Liquid broth after 48 hour incubation 
A B 
Figure 2.2  M. felis colonies  
(Olympus CKX41 x40) after 48 hours 
incubation (typically 0.15-0.3 µm in 
diameter) 
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Table 2.3  VCC results for different growth phase cultures of M. felis strain 
10160 
        
Growth Phase Viable count (ccu/ml)     
lag 106 107 106     
lag +2 106 107 107     
log 106 106 106     
        
 
2.3.3 Enrofloxacin Efficacy 
Two pH adjustments were required for enrofloxacin, at day 27 and day 33 as the 
pH had become slightly acidic (from pH 7.2 to pH 6.8 and pH 6.7 respectively).  
The strain 10160 MIC results for enrofloxacin were as follows:  1/13 result of 
0.25µg/mL (8%) and 12/13 results of 0.125µg/mL (92%).  These results show no 
significant shift or deterioration in efficacy of the enrofloxacin stock solution 
over a 5 month period. 
2.3.4 Minimum Inhibitory Concentration (MIC) Testing 
The MIC results of all clinical isolates and strain D8 are shown in Appendix 2.  Of 
the isolates tested, 11 had viable counts out-with the required range, with a 
further 2 agar plates showing contamination after 48 hours culture.  These 
isolates were purified where necessary and the VCC and MIC tests were 
repeated. 
The antimicrobial control, ampicillin, was proven to be ineffective as expected, 
with an MIC90 of >64 µg/mL for all clinical isolates and the reference strain 
tested.  The most effective antimicrobial tested was the bactericidal 
fluoroquinolone, pradofloxacin, with MIC90 of 0.03125 µg/mL shown to be 
effective at eliminating growth in vitro.  Isolates were also highly susceptible to 
doxycycline with an MIC90 of 0.0625 µg/mL, in comparison to oxytetracycline 
with an MIC90 of 1 µg/mL.  Most isolates appeared resistant to both macrolides 
with erythromycin being least effective, recording MIC values of ≥8 µg/mL for all 
isolates; 28 isolates (55%) showing MIC values of ≥64 µg/mL and azithromycin 
Performed in triplicate, Viable Cell Count (VCC) results are shown above for 
M. felis reference strain 10160 in varying growth phases.   
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demonstrating an MIC90 of ≥32 µg/ml for clinical isolates and the reference 
strain.   
MIC values for each antimicrobial were mostly consistent for each isolate tested; 
MIC distribution was within 3 dilutions for more than 90% of clinical isolates for 
each antimicrobial.  Enrofloxacin exhibited the greatest range in antimicrobial 
activity among clinical isolates, ≤0.03 - 8 µg/mL. Six isolates appeared resistant 
to enrofloxacin, with MIC values of ≥ 2 µg/mL.  All MIC50 and MIC90 values for 
clinical isolates are shown in Table 2.4.  The MIC50 and MIC90 values for the 
reference strain can be seen in Table 2.5.  When comparing the MIC50 values of 
reference strain 10160 against the clinical isolates, the results for the 
fluoroquinolones were identical.  For the macrolides and tetracyclines, a 
difference of only one dilution was observed.  MIC90 values were also consistent 
across the range of antimicrobials tested, with the exception of enrofloxacin for 
which the MIC90 was 0.125 µg/mL for reference strain 10160 in comparison to the 
clinical isolates with an MIC90 of 2 µg/mL. 
Those isolates with MIC values showing non-conformance were selected for 
repeat testing.  The reference strain results for enrofloxacin were highly 
consistent, with an MIC of 0.125 µg/mL for 12 of 13 runs, and one at 0.5 µg/mL.  
This is in contrast to the results from the isolates tested, demonstrating the 
greatest range in antimicrobial activity, reflected in the MIC range for 
enrofloxacin (0.03125 µg/mL to 8 µg/mL).  Three isolates were retested as their 
initial MIC values for doxycycline were higher than expected (8 µg/mL, 1 µg/mL 
and 4 µg/mL), when compared to the MIC90 (0.0625 µg/mL).  Upon repeat 
testing, each doxycycline MIC value fell to within the consistent range and MIC50 
and MIC90 values were adjusted accordingly for final results (Table 2.4). 
 
43 
 
Table 2.4 MIC distribution for M. felis clinical isolates          
                 
  Concentration Range (µg/mL)   
Antimicrobial   >64 64 32 16 8 4 2 1 0.5 0.25 0.125 0.0625 0.03125 MIC50a MIC90b 
Azithromycin 
N
u
m
b
e
r 
o
f 
Is
o
la
te
s 
1 1 8 11 11 12 6 1           8 32 
Doxycycline                     5 11 35 0.03125 0.0625 
Enrofloxacin         1 2 3 1 1 3 30 3 7 0.125 2 
Erythromycin 5 23 12 7 4                 64 64 
Oxytetracycline             2 21 20 3   2 3 0.5 1 
Pradofloxacin                   2 2 3 44 0.03125 0.03125 
Ampicillinc 51                         >64 >64 
                 
a Concentration required to inhibit growth in 50% of isolates (26 isolates) 
b Concentration required to inhibit growth in 90% of isolates (46 isolates) 
c  Ampicillin was used as a negative control 
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Table 2.5  MIC distribution for M. felis reference strain NCTC 10160          
                  
  Concentration Range (µg/ml)    
Antimicrobial   >64 64 32 16 8 4 2 1 0.5 0.25 0.125 0.0625 0.03125 MIC50 MIC90  
Azithromycin 
N
u
m
b
e
r 
o
f 
Is
o
la
te
s 
    2 5 5 1               16 32  
Doxycycline                     3 6 4 0.0625 0.125  
Enrofloxacin                 1   12     0.125 0.125  
Erythromycin     10 3                   32 32  
Oxytetracycline           1 5 7           1 2  
Pradofloxacin                         13 <0.03125 <0.03125  
Ampicillin  13                         >64 >64  
                  a Concentration required to inhibit growth in 50% of isolates 
b Concentration required to inhibit growth in 90% of isolates 
c  Ampicillin was used a negative control 
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2.3.5 Determination of Biostatic or Biocidal Activity 
Pradofloxacin and enrofloxacin were identified as bactericidal at the minimum 
concentration 0.03125µg/mL.  Azithromycin and erythromycin were shown to be 
bactericidal at the highest concentration tested (64 µg/mL) but were otherwise 
bacteriostatic.  All other antimicrobial drugs were demonstrated to be 
bacteriostatic, regardless of concentration. 
2.3.6 Haemolysin Activity 
All isolates except one were cultured on SB and shown to be haemolytic, with 25 
showing β-haemolysis and 25 showing α-haemolysis.  The isolate which could not 
be cultured on SB was cultured on AG and sub-cultured after 48 hours to horse 
blood agar where it was observed to be alpha haemolytic.  
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2.4 Discussion 
Historically the first line of treatment of M. felis, and mycoplasmosis in general, 
is the tetracyclines (Kibeida, 2010).  This group of antimicrobials have been well 
established in human and veterinary medicine.  Resistance to tetracyclines has 
been acknowledged to be emerging amongst a variety of bacterial genera, 
including mycoplasmas, with numerous mutated genes identified in the 
mechanism of resistance (Taylor-Robinson and Bébéar, 1997, Schwarz and 
Chaslus-Dancla, 2001, Morley et al., 2005, Reller et al., 2009, Blanchard and 
Bebear, 2011, Schultz et al., 2012).  One study  found that M. bovis 
demonstrated an MIC90 of 32 µg/mL for doxycycline (Man et al., 2012).  This 
resistance to the tetracyclines was not reflected by other isolates tested by Man 
et al., with M. pneumoniae, M. genitalium, M. homins, M. fermentans, M. 
hyosynoviae and M. hyopneumoniae having MIC90s consistently below 2 µg/mL.  
Although still higher than the MIC90 observed in this project (0.0625 µg/mL) this 
indicates that although emerging, resistance may be isolated to particular 
species of mycoplasma.  The Kibeida (2010) study also supports this; the 
doxycycline MIC90 for M. felis recorded in that study was 0.25 µg/mL, much 
closer to the MIC90 observed in this project. 
All clinical isolates and the reference strain used in this project showed highest 
susceptibility to pradofloxacin.  Pradofloxacin is the only third generation 
quinolone currently approved for use with companion animals (Sykes and Papich, 
2014b) and the guidelines promote its conservative use, recommending it is 
avoided as a first line of treatment, in order to minimise developing resistance 
(Morley et al., 2005, Weese, 2006).  Enrofloxacin is employed in human and 
animal medicine, whereas pradofloxacin is licensed specifically for animals only 
(dogs and cats) (Health, 2013).  Due to concerns regarding retinal toxicity, the 
use of enrofloxacin in the treatment of cats is now uncommon (Gelatt et al., 
2001) yet, being licensed for use in human and animal medicine does suggest 
that enrofloxacin is likely more regularly employed than pradofloxacin, thus 
increasing the likelihood of emerging resistance to this drug.  However, taking 
the outlying MICs into account, the enrofloxacin MIC50 of 0.125µg/ml is still 
notably lower than the macrolides tested and slightly lower than oxytetracycline 
(MIC50 0.5µg/ml).  Kibeida (2010) found the MIC90 of enrofloxacin to be 0.031 
µg/mL which is remarkably lower than the MIC90 observed during this project (2 
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µg/mL).  This apparently higher MIC90 may be attributed to the inability to 
repeat test those isolates with outlying values.  This is supported by the MIC50 
0.125 µg/mL and that 78% (40 isolates) were inhibited at this concentration or 
below.   
Although it would have been preferable to repeat test the isolates with outlying 
MIC results, numerous genes, and their subsequent mutations, have been 
identified in fluoroquinolone resistance.  Therefore it may prove useful to check 
for the presence of those so far identified, once the sequencing information is 
available, to determine if mycoplasmas are developing resistance to this drug.  
Of other studies reviewed, Mycoplasma hominis, M. hyosynoviae, M. bovis and 
M. hyopneumoniae were noted to have decreased susceptibility to macrolides, 
particularly erythromycin (Taylor-Robinson and Bébéar, 1997, Vicca et al., 2004, 
Man et al., 2012), with M. bovis having an MIC90 of >128µg/mL (Taylor-Robinson 
and Bébéar, 1997),  however M. pneumoniae, M. genitalium and M. fermentans 
showed MICs of less than 1µg/mL (Taylor-Robinson and Bébéar, 1997). 
The decreased susceptibility to macrolides observed in this project echoes these 
previous studies and may reflect the long-standing use of erythromycin in 
veterinary and human medicine. Interestingly erythromycin, although requiring 
higher MICs, demonstrated bactericidal properties when reference strain 10160 
was tested.  The MIC was 32µg/mL which, when removed onto an agar plate, 
showed recovery and growth of M. felis.  However, the higher concentration 
(64µg/mL) was also removed onto agar and showed no growth, indicative of 
bactericidal action.  The macrolides are acknowledged to have bactericidal 
properties at high concentrations but for this difference to be observed over one 
dilution, particularly when susceptibility was apparently low, was unexpected. 
It is important to note that although a range of MICs were recorded for each 
antimicrobial, these did not seem to represent emerging resistance over time.  
The clinical isolates spanned 6 years (2008-2014), with the D8 strain from 1997 
and the 10160 reference strain from 1967.  When the MIC50 results of the 
reference strain 10160 are compared to the results of the clinical isolates, there 
is an increase of only one dilution concentration for the macrolides and 
tetracyclines, with the fluoroquinolone MIC50s being identical. 
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A total of 51 M. felis isolates plus the 10160 reference strain were MIC tested 
using the liquid broth method previously published by Hannan (2000) and 
validated again recently by Kibeida (2010).  The isolates demonstrated the 
fragile and fastidious nature characteristic of mycoplasmas, with 19 original 
isolates failing to recover from freeze storage and a further 8 isolates failing to 
reach sufficient concentrations for testing even after concentration. 
Interestingly, a number of the recovered isolates demonstrated notable growth 
after only 24 hours incubation, with some showing visible growth after only 16 
hours, contradicting the expected slow growth of mycoplasmas.  Of those which 
did reach the required VCC, initial results proved problematic, with numerous 
viable counts not being reproduced during the MIC.  It was considered that the 
VCC should be performed in duplicate, and so 8 isolates were selected at 
random, removed from storage and processed for VCC.  Although each VCC was 
performed with isolates processed identically, from the same frozen aliquot and 
same incubation vacuette, 4 of the 8 isolates tested in duplicate showed 
variance of one doubling dilution in viable counts.  This demonstrated an 
inherent variability in growth and viability of the mycoplasmas.  The 
mycoplasmas are known to be fragile so this variability may be attributable to 
the sometimes long-term storage affecting viability or that they were viable but 
not cultivable in the time frame allocated.  Nevertheless, these data indicated 
that a margin of error should be accounted for when diluting inoculum for MIC 
testing.  Subsequent VCCs were performed singly for each isolate.  Inoculum 
dilutions were calculated to obtain a 104ccu/ml concentration for MIC, allowing 
for a doubling dilution on either side which would still fall within the range for 
standardised inoculum recommended by Hannan (2000) which was verified in the 
VCC included when MIC testing. 
While preparing VCCs and working with another research student also preparing 
MIC plates, it was observed that LB thawed on the bench and LB thawed in a 
37°C water bath were subtly different in colour.  Both bottles of LB were from 
the same lot and had been stored in the same conditions so the difference in 
colour was unusual.  The LB thawed in the water bath was marginally darker red 
than the LB thawed on the bench.  The pH of both bottles was tested, with no 
discernible difference.  The dependence of colour changes in the media for MIC 
results required we reduce the likelihood of any colour change not indicative of 
49 
 
growth. Given this, it was considered that the water bath and the incubator 
temperature was equal, therefore if temperature could affect colour then all LB 
should subsequently thawed in a water bath.   
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Chapter III 
Genetic Sequencing and Analysis of Mycoplasma felis Clinical Isolates 
3.1 Introduction  
Thus far, the pathogen status of M. felis is ambiguous. Mycoplasmas 
acknowledged to be pathogenic have been identified as expressing a variety of 
virulence factors, including lipoproteins, nucleases and adhesins (summarised in 
Table 3.2).  Full genome sequencing of M. felis, identifying the presence of 
known mycoplasma virulence genes, would provide insight into its pathogenicity 
and potentially allow a clearer definition of its role as a pathogen in cats, 
allowing informed decisions to be made regarding treatment.  Phenotypic data 
corresponding to antimicrobial resistance has been obtained during this study, 
providing the opportunity to potentially correlate M. felis phenotype with 
genotype as well as identify any emerging resistance; it would therefore be 
prudent to investigate the M. felis data for known antimicrobial resistance 
genes. 
Mycoplasma lipoproteins are known to interact with host immune cells, via toll-
like receptors (TLRs) or by acting as cytokine inducers for host monocytes and 
macrophages, ultimately having the potential to induce or prevent apoptosis 
(Into et al., 2002, Sasaki et al., 2002, Gerlic et al., 2007, Zuo et al., 2009).  
Lipoproteins, have been described as one of the most important factors in 
pathogenic activity (Feng et al., 1999, Zuo et al., 2009), consequently the 
identification of known lipoproteins in M. felis would be of great interest and 
beneficial in determining its status. 
Nuclease activity has been identified in pathogenic mycoplasmas such as M. 
pulmonis, M. hyorhinis, M. fermentans and M. penetrans (Minion et al., 1993, 
Paddenberg et al., 1998, Chambaud et al., 2001).  These nucleases may be 
integral or peripheral membrane proteins which mycoplasmas are capable of 
secreting.  It has been suggested that mycoplasmas use these endogenous 
nucleases to procure precursors of DNA synthesis (Minion et al., 1993, 
Paddenberg et al., 1998).  Although mycoplasma nucleases have been shown to 
be harmless to host cells under normal conditions, stressed cells allow these 
proteins to enter internucleosomal sites, thus enabling degradation of host DNA 
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(Paddenberg et al., 1998).  Investigating the M. felis genome, to search for the 
genes encoding these proteins may allow insight into its pathogenicity.   
Adhesins have been described in pathogenic mycoplasmas including M. bovis and 
M. pneumoniae with their roles in cytadherence and antigenic variation being 
well characterised (Dallo et al., 1996, Sachse et al., 1996, Chourasia et al., 
2014).  Adhesins are crucial for colonisation and infectivity and therefore 
virulence (Razin and Jacobs, 1992), thus their presence or absence in M. felis 
would be another step forward in defining its role. 
Whilst exploring the potential pathogenicity of M. felis, it would be of benefit to 
veterinarians if any emerging antimicrobial resistance could be identified.  
Homologues of the tetM antibiotic resistance gene found in Streptococcus have 
also been identified in mycoplasmas (Roberts et al., 1985) indicating that they 
are capable of acquiring genes as well as being highly mutable (Razin et al., 
1998, Blanchard and Bebear, 2011).  Emerging fluoroquinolone resistance has 
also been identified in mycoplasmas, with researchers revealing a previously 
characterised mutation in the quinolone resistance determining region (QRDR) of 
the ParC gene, known to confer resistance (Lysnyansky et al., 2013).   
Varying degrees of haemolytic activity have been observed in most mycoplasmas 
(Minion et al., 1993), with numerous haemolysin encoding genes having now 
been identified.  Cole et al. identified haemolytic activity, describing peroxide 
as the major haemolysin within mycoplasmas (Cole et al., 1968).  Given that 
haemolytic activity of M. felis has been observed during culture, it would be 
reasonable to search for the presence of a corresponding gene.  
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3.2 Materials and Methods 
3.2.1 Mycoplasma felis DNA Extraction 
All clinical isolates which demonstrated a viable cell count of 103 ccu/ml or 
greater in earlier testing (52 plus reference isolate), were selected for 
extraction of nucleic acids. Mycoplasma felis genomic DNA was extracted from 3 
mL of logarithmic growth phase liquid broth cultures, using the QIAamp DNA Mini 
Kit as per manufacturer’s instructions.  For each isolate being extracted, a 
purity plate was set up from the same liquid broth culture in order to identify 
any possible contamination.  Mycoplasma DNA is fragile in nature therefore the 
protocol was modified, firstly to process 3 mL instead of 1 mL of culture to 
increase DNA yield, and also all steps were performed on ice and centrifugation 
at 4°C, in order to inhibit endogenous nucleases.  The proteinase K incubation 
time was also reduced to 10 minutes. Elution volumes were reduced to 50 µL to 
concentrate mycoplasma DNA within each extract and DNA extracts were stored 
at -20°C.  Sufficient DNA for sequencing was obtained from 50 clinical isolates 
and the reference strain 10160.  The sequencing kit selected was able to 
multiplex only 48 samples, therefore 3 clinical isolates which had shown little 
overall phenotypic difference were selected to be omitted from sequencing in 
order to allow space for the reference strain and 47 clinical isolates. 
3.2.2 DNA Template Preparation for Next Generation Sequencing                             
3.2.2.1 Quantification 
Extracted mycoplasma DNA was quantified using a Qubit®fluorometer (Life 
Technologies, Paisley, UK).  The Qubit allows fluorometric quantification of 
double stranded (dsDNA) by detecting the signal from an intercalating 
fluorophore, only emitted when bound to the target dsDNA.  This allows an 
accurate measure of the concentration of dsDNA available which is essential for 
Next Generation Sequencing (NGS).  Briefly, the equipment was calibrated using 
the supplied standards as per manufacturer’s instructions.  20 µL of mycoplasma 
extract was added to an optical tube containing 180 µL of dilution buffer, 
prepared according to manufacturer’s instructions (1 µL Quant-iT reagent plus 
199 µL Quant-iT buffer per mycoplasma extract).  The mixture was then briefly 
vortexed, taking care to avoid bubbles before being read on the fluorometer. 
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3.2.2.2 Tapestation 
The Agilent 2200 TapeStation (Agilent Technologies UK Ltd, Edinburgh, UK) 
separates, images and analyses fluorescently labelled dsDNA (35-1000 bp) within 
a closed electrophoresis system (Padmanaban et al., 2013), using a ScreenTape 
instead of a gel, and ultimately providing an electropherogram as well as a 
traditional gel image to size and quantify DNA fragments. 
TapeStation consumables were removed from refrigeration at 4°C and allowed 
to come to room temperature. 3 µL of High Sensitivity D1K Ladder was added to 
the first optical tube and capped.  This ladder provides a control for both the 
validity of the ScreenTape and the electrophoresis, as fragments sizes are 
known.  2 µL of each isolate extract was added to separate tubes with 2 µL of 
sample buffer, capped and briefly vortexed to mix. All samples were centrifuged 
briefly before being loaded onto the TapeStation instrument and initiating 
electrophoresis via computer software. The electropherogram generated was 
used to check the quality of the extracted mycoplasma DNA by quantifying the 
number and size of fragments within the tested extract. 
3.2.3 Optimisation of DNA Shearing and Size Selection 
Fragmentation of DNA is required to ensure the length is compatible for 
sequence library generation and subsequent clustering on the desired sequencing 
instrument.  The Covaris™ S220 Focused-ultrasonicator™ (Life Technologies, 
Renfrew, UK) fragments DNA by hydrodynamic shearing, in which the sample is 
exposed to short bursts of sonication.  This mechanical shearing of DNA is very 
reliable, allowing control of the average shear size and making it ideal for NGS. 
In this case 300-500 bp, was the optimal size range to match the Illumina MiSeq 
platform used in this study. 
AMPure XP Beads (Beckman Coulter Inc., High Wycombe, UK) utilise an optimised 
buffer (polyethylene glycol and sodium chloride) and magnetic beads selectively 
bind negatively charged DNA fragments.  These beads are used routinely in 
molecular biology laboratories to purify PCR amplicons by binding to larger DNA 
fragments and allowing excess primers, nucleotides and salts to be removed in 
the supernatant.  An elution step then releases the bound DNA.  The 
concentration of these beads may be varied in order to selectively bind DNA 
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fragments of particular sizes, allowing size selection, and thus the fine-tuning of 
DNA fragment size range for sequencing. 
To optimise the sonication and AMPure bead clean up (detailed below), several 
sonication treatment times were tested to identify the optimal fragment size 
range of sheared mycoplasma DNA.  Isolates were run on the TapeStation to 
determine which sonication time and bead concentration yielded the best DNA 
fragment size range for DNA library preparation. 
3.2.3.1 DNA Fragmentation (Shearing) by Focused Ultrasonication 
50 µL of each mycoplasma extract was added to a microTUBE (Covaris, Brighton, 
UK) and capped.  Each microTUBE was then loaded onto the Covaris™ S220 and 
sonicated for 75 seconds with the following parameters: peak incident power – 
175 W; duty power - 5%; number of cycles per burst -200.  Following sonication, 
isolates were stored at 4°C until clean up. 
3.2.3.2 Use of AMPure XP Beads for Size Selection 
Following sonication, all mycoplasma extracts were mixed with 0.7x AMPure XP 
beads in order to remove fragment sizes smaller than 300 bp.  Numerous 
protocols were available, each with slight variations in recommended 
concentrations, therefore optimisation was required. The following method was 
the most effective protocol for recovery of mycoplasma DNA.  Beads were 
allowed to come to room temperature (RT) for 30 mins.  50 µL of each 
mycoplasma extract was dispensed into separate wells of a 96-well plate and 35 
µL of AMPure beads added to each extract before mixing slowly 10 times with 
gentle pipetting.  After 5 mins incubation at RT the plate was moved to a 
magnet till the solution cleared and the beads had formed a pellet before 
removing the supernatant.  The beads were allowed to dry for 2 mins at RT.  
Each pellet was then flooded with 100 µL of 70% ethanol (freshly prepared) and 
drained using a pipette and the process repeated.  The plate was removed from 
the magnet and the pellet resuspended in 50 µL of 10 mM Tris by pipetting 
gently and incubating at room temperature, for 2 mins, before putting the plate 
back onto the magnet.  The beads were allowed to form a pellet and once 
completely clear, the eluate, with the selected size fragments in suspension, 
was then transferred to a fresh well before quantification and library 
preparation. 
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Following optimisation, all of the mycoplasma extracts to be sequenced were 
sonicated and size selected using the optimised protocol.  A number of these 
size selected extracts were subsequently electrophoresed on the TapeStation to 
ensure the size selection procedure had indeed been optimal and consistent. 
3.2.4 DNA Library Preparation 
The ThruPLEX®DNA-seq Kit (Rubicon Genomics, Cambridge) was selected as it 
fitted a number of criteria desired for our library preparation method.  It was 
able to process as little as 50 pg of template DNA which was necessary because 
of the low DNA yield obtained from our Mycoplasma isolates as well as 
generating good diversity of libraries obtained when compared with other 
leading commercial brands, whilst also allowing the efficient and simultaneous 
sequencing of 48 isolates. In addition, indexing reagents and the ThruPLEX® 
stem-loop adaptors were already pre-dispensed in a 48-well format to allow a 
three-step, single-tube reaction, which reduced manipulations and as a result 
meant less scope for contamination.   
The mycoplasma DNA templates were prepared, and library synthesis was 
completed according to manufacturer’s instructions.  The Rubicon kit uses 
ThruPLEX® technology, based on stem-loop adaptors (Fig 3.1).  The optimal 
number of cycles for amplification was determined as eight, using the DNA 
concentration obtained prior to library preparation to inform the estimation 
process as detailed in the manufacturer’s instructions. 
The amplified DNA was purified using AMPure beads, as described above, to 
remove primers and adaptor dimers prior to sequencing.  In accordance with 
guidelines from Illumina (Essex, UK) a DNA concentration of 4 nM was required 
for denaturation prior to sequencing.  Library quantitation is essential to allow 
efficient multiplex sequencing and optimal cluster density for the flow cell. The 
concentration of the pooled library was calculated by a combination of the 
concentration measured by Qubit and the average insert size by Tapestation 
using the following formula: 
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Figure 3.1 Calculation of Library Molar Concentration 
The amount of DNA (ng/ul) was obtained for each isolate extract using the 
Qubit, with peak size being obtained using the TapeStation.  These 
concentrations were recorded for each extract in order that they could be 
pooled for multiplex sequencing.  At this stage one clinical isolate was removed 
from the panel for sequencing as the concentration was too low.  The remaining 
46 isolates plus reference strain 10160 were sufficient to continue. 
The 47 remaining template libraries were then diluted, using the supplied 
hybridization buffer, to a concentration of 4 nM to ensure equal concentrations 
of each template.  The 4 nM libraries were then denatured using a fresh NaOH 
solution before all samples were pooled for multiplex sequencing. The pooled 
DNA was again tested on the Tapestation and Qubit to ensure the correct 
concentration and fragment size were achieved. 
For improved quality control during sequencing, the pooled library was diluted 
and the internal control, PhiX, added at 1% before commencing the sequence 
run as recommended by Illumina. The PhiX genome is well defined and diverse, 
with balanced nucleotides.  Given that Illumina has optimised cluster detection 
for balanced representation of adenine, thymine, guanine and cytosine 
nucleotides, the addition of PhiX allows a more diverse set of clusters.  This is of 
particular importance for mycoplasma sequencing as they are known to possess 
low-GC content and therefore the cluster diversity provided by PhiX becomes 
crucial.  Sequencing was carried out on the MiSeq Illumina) platform, generating 
150 bp paired-end reads. 
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Figure 3.2 ThruPLEX DNA-seq Technology  (Rubicon, 2012) 
 
Initially, the DNA template is repaired to provide blunt ends with which the 
stem-loop adaptors can ligate.  The adaptors 5’ ends are blocked, leaving a gap 
at the 3’ end.  They cannot ligate to each other, and lack the single strand tail 
typical of Y adaptors, therefore reducing background ligations.  The template 
DNA is extended and then amplified, at which point Illumina compatible indexes 
are added. The final library product for NGS has sequencing primers, index tags 
and P5/P7 termini on either side of the isolate DNA.  The P5 and P7 termini are 
defined sequences, complimentary to sequences on the surface of the flow cell, 
allowing the termini and attached library fragment to bind to the flow cell for 
sequencing. 
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3.2.5 Next Generation Sequencing                                                                                      
The MiSeq Illumina NGS platform is capable of producing paired reads of 300 bp 
through parallel sequencing of the fragmented DNA pool.  The capability of 
multiplex sequencing, using indexed samples (Fig 3.2 and Fig 3.4), reduces time 
and cost, and in this case, allows the simultaneous sequencing of 47 M. felis 
isolates.  The pooled DNA was briefly centrifuged before being added to the 
MiSeq reagent cartridge (Figure 3.3) and loaded into the MiSeq and the Rubicon 
index sequences added to the software setup as per manufacturer’s instructions. 
 
                         
Figure 3.3  MiSeq and Consumables 
This single use reagent cartridge is pre-filled with sequencing reagents.  The 
prepared sample libraries are added to the highlighted aperture while the other 
apertures allow access to separate reagents required during the process.  The 
cartridge is then loaded onto the MiSeq, shown on the right.  Image obtained 
from Illumina Inc. 
Unique 8 nucleotide dual indexes are attached to each library during 
preparation, allowing the libraries to be pooled and loaded in the same flow 
cell.  Libraries are then sequenced in one MiSeq run, with all generated 
sequences being exported in a single data file.  The index sequences are then 
sorted using Illumina software to create different file for each template.   
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Figure 3.4 Overview of Library Multiplexing/Demultiplexing for Analysis  
(Illumina, 2016) 
 
3.2.6 Mycoplasma felis Sequence Analysis 
3.2.6.1 Pre Analysis Data Trimming 
The sequence data for 46 clinical isolates, and the reference strain 10160, were 
trimmed of adapters and subsequently further trimmed of 25 bp on each end, 
using CLC Genomics Workbench 7.5.1 software (CLC), to improve overall 
sequence quality of the usable data set (Fig 3.7). This read trimming step is 
crucial in NGS analyses as contamination of the data with adaptor or primer 
sequences may result in alignment errors or an increased number of unaligned 
reads in downstream analyses. 
3.2.6.2 De novo Assembly 
The purpose of de novo assembly is ultimately to produce a novel genome 
sequence.  Through the assembly of short sequence reads, larger contiguous 
sequences (contigs) are produced which may then be further assembled to 
create scaffolds.  Using the CLC software standard parameters for de novo 
assembly, contigs were generated, initially for the mycoplasma reference strain 
10160 and then for a further 12 of the 46 isolates (selected according to number 
of reads generated in sequencing, ensuring a wide range – Table 3.3).  For best 
results, a low number of contigs with a high depth of coverage is required.  
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Standard CLC de novo assembly parameters allow this to be measured, firstly by 
reporting the number and length of contigs generated (excluding those <200 bp), 
but also providing the option of mapping reads back to the newly generated 
contigs, thus allowing depth of coverage to be determined. 
Unfortunately, de novo assembly failed to provide a reference scaffold; upon 
examination of the generated contig sequences, much of the data appeared to 
be non-coding, low complexity sequence with poor depth of coverage.  With the 
time involved in attempting to de novo assemble these for 12 isolates and the 
reference isolate; it was clear that not all planned analyses could be done for 
each of the 47 isolates.  The 12 isolates selected for de novo assembly, along 
with the reference strain 10160 were therefore used for all further analyses. 
3.2.6.3 Alignments Using the Basic Local Alignment Search Tool (BLAST) 
Newly generated reads may be investigated using BLAST databases which 
catalogue whole genomes, scaffold genomes and individual gene sequences 
previously sequenced and published.  Using BLAST, the newly generated reads 
can be aligned, or mapped, to existing genetic sequences.  Generally using a 
reference sequence, these alignments allow comparison and identification of 
variation.  A selection of the largest contigs generated for reference strain 10160 
were run using the Basic Local Alignment Search Tool (BLAST) to the NCBI 
nucleotide (blastn) database however results were inconsistent and we were 
again unsure if the contigs were accurate.   
The top contigs for each of the 12 clinical isolates were run in BLAST, however 
remained inconsistent.  These results left us unsure if the contigs were accurate 
enough to pursue further analyses at this stage.  Using the trimmed reads 
themselves, without assembly, the BLAST hits became more consistent with 10 
of the 13 selected isolates returning the same organism – Mycoplasma cynos as 
most homologous.  The remaining two isolates (both of which had a very low 
number of reads available) returned Mycoplasma canis as the top result with 
Mycoplasma cynos being second.  At this stage, Mycoplasma cynos was selected 
as a reference genome.      
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3.2.6.4 Alignments Using Mycoplasma cynos as a Reference Genome                                      
Trimmed reads for each isolate were used for all subsequent alignments and 
BLAST analyses.  The M. cynos genome identified as similar in BLAST was then 
imported to CLC for alignments with the reference strain 10160 and all 46 
clinical isolates.   
3.2.6.5 Other Alignments 
A selection of mycoplasma whole genome sequences (WGS) and individual gene 
sequences were imported from BLAST to CLC for alignment and comparison. The 
WGS were selected as they share the same phylogenetic grouping (fermentans) 
as M. felis (Brown et al., 1995) or because they showed high similarity in BLAST.  
To identify any emerging resistance or virulence factors in the M. felis isolates, 
individual genes were selected which were well characterised in other 
organisms.  These included known antimicrobial resistance genes, genes 
inferring haemolytic activity and those of known mycoplasma lipoproteins, 
nucleases and adhesins proven to increase virulence in other mycoplasmas. All 
imported files (Table 3.1 and 3.2) were then aligned for comparison with the M. 
felis reference strain 10160 and clinical isolate reads. 
Since isolate 3 returned the largest number of reads, after alignment with the 
M. cynos whole genome, the unmapped reads were then exported to a FASTA file 
to be run on BLAST in order to determine if these reads would correspond to any 
other organism. 
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Table 3.1 Mycoplasma whole genome sequences within the M. fermentans 
phylogenetic grouping, which were aligned against trimmed reads from the 
M. felis clinical isolates 
Mycoplasma Genome Accession Number 
M. cynos C142 HF559394 
M. fermentans M64 CP002458.1 
M. felis ATCC23391(partial) KL370829 
M. bovis NM2012 CP011348 
M. pneumoniae M129 NC_000912 
M. pulmonis UAB CTIP AL445566 
M. agalactiae PG2 NC_009497 
M. hyopneumoniae 232 AE017332 
M. mycoidesstr PG1 NC_005364 
M. synoviae NZ_ARQH01000042 
M. gallisepticum CP006916 
M. genitalium CP003770 
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Table 3.2 Well-characterised virulence genes, aligned with trimmed reads 
from the M. felis reference strain and clinical isolates. 
Organism Gene/Protein Description 
Accession 
No. 
M. cynos hapA 
haemagglutinin 
(cytadherence) KJ997962 
Escherischia coli hha haemolysin AF294319 
Staphylococcus 
aureus Hla alpha haemolysin KM019673 
M. cynos hlyA, B, C, D haemolysin HF559394 
U. ureaplasma hlyC haemolysin NC_002162 
M. pneumoniae 
M129 hmw1 
cytadherence accessory 
protein NC_000912 
M. pneumoniae 
M129 hmw2 
cytadherence accessory 
protein NC_000912 
M. pneumoniae 
M129 hmw3 
cytadherence accessory 
protein NC_000912 
M. putrefaciens LppB transport protein EU429511 
M. genitalium TlyC haemolysin CP003770 
M. hyopneumoniae nuc exonuclease AE017332 
M. agalactiae P80 membrane lipoprotein X95628 
M. pulmonis  Mnu membrane nuclease U38841 
M. gallisepticum MslA nuclease co-operation CP001872 
M. hyopneumoniae MnuA nuclease AE017332 
M. hyopneumoniae MnuA nuclease NC_007295 
M. penetrans MYPE4380 nuclease NC_004432 
M. pulmonis  MYPU_6940 membrane nuclease AL445565 
M. pulmonis  MYPU_6930 
membrane nuclease, 
lipoprotein AL445565 
M. pulmonis  MYPU_1390 nuclease, lipoprotein AL445565 
M. hominis OppB, C, D, F 
cytadherence, ATPase 
activity X99740 
M. mycoides OppA, B, C 
transmembrane 
permease KM410303 
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Organism Gene/Protein Description 
Accession 
No. 
 
M. pneumoniae  orf6 cytadherence Z33397 
M. pneumoniae P1 cytadherence AF290000 
M. pneumoniae P1 cytadherence JN048896 
M. pneumoniae P1 cytadherence AB024618 
M. pneumoniae P1 cytadherence AF286371 
M. agalactiae P80 membrane lipoprotein NC_009497 
Enterococcus 
faecium parC 
fluoroquinolone 
resistance LN624829 
M. gallisepticum parC 
fluoroquinolone 
resistance AF372652 
M. synoviae parC 
fluoroquinolone 
resistance AY819792 
M. felis (strain CO) rpoB transcription DQ234670 
Streptococcus 
pneumoniae tetM tetracycline resistance AY466395 
M. gallisepticum tetM tetracycline resistance GQ424446 
M. hyopneumoniae TlyA haemolysin AF326115 
M. felis (strain CO) tuf elongation factor FJ896397 
M. bovis 
VspE, A, F, J, B, K, L, 
M, N, O Lipoprotein AF396970 
M. bovis VspE, C, F Lipoprotein AF396972 
M. gallisepticum VlhA haemagglutinin EU284138 
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3.3 Results  
3.3.1 Mycoplasma felis DNA Extraction 
Following optimisation of the manual extraction process, to increase DNA 
available for harvest and ensure inhibition of endogenous nucleases, the DNA 
yield was improved.  Sufficient DNA was obtained from 50 clinical isolates plus 
the reference strain 10160. 
3.3.2 DNA Template Preparation for Next Generation Sequencing 
The DNA yield obtained from the Mycoplasma felis samples ranged from 0.6 – 1.7 
ng/µL. 
3.3.3 Optimisation of DNA Shearing and Size Selection 
 
 
 
 
 
Figure 3.5 Traditional gel image and electropherogram comparing 
various sonication times  
Traditional gel image and electropherogram comparing various sonication 
times to quantify the number and size of fragments within the tested 
mycoplasma extract in order to determine optimal time to retrieve the 
desired fragment sizes for NGS.  
A1 - High sensitivity D1K Ladder, B1 - 35 sec sonication of mycoplasma 
isolate,  C1 - 45 sec sonication of mycoplasma isolate,  D1 - 60 sec 
 
 
B1 C1 D1 
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The smear at the lower size range of each lane in the gel image is indicative of 
some degradation.  Mycoplasmas are very fragile and therefore this observation 
is not entirely unexpected.  The high molecular weight band at the top of each 
gel lane is indicative that substantial larger fragments are still present. The 
electropherogram mirrors this result, showing a left shift in the central peak 
with increasing sonication time.  This demonstrates only a minimal increase in 
the number of smaller fragments but showing only a minimal reduction in the 
number of large fragments, leaving a significant number still too large for NGS.  
Therefore extended sonication times were tested. 
 
 
 
The electropherogram shows a subtle left shift at 75 seconds sonication with a 
slight increase in the number of fragments between 100 and 300 bp in size. 
However, it also shows a slightly reduced quantity of fragments of 1000-1500 bp.   
A peak remains indicating that larger fragments are still present.  Given that the 
optimal fragment size for the selected sequencing kit was 300-500 bp, 75 
seconds sonication was chosen and applied for all extracts to be sequenced.  
 A  B 
Figure 3.6 Electropherogram comparing 60 second and 75 second sonication time of 
mycoplasma extract 
A -60 sec sonication of mycoplasma isolate, B -75 sec sonication of mycoplasma isolate 
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Figure 3.7 Electropherograms showing comparison of mycoplasma extracts 
sonicated for 75 seconds and cleaned up using 0.7x (A) and 0.8x (B) AMPure 
bead concentrations. 
This comparison shows peak size to be similar for both AMPure bead 
concentrations, however distribution is more compact using the 0.7x 
concentration, with markedly fewer fragments of <200 bp which would be more 
suited to NGS.  The large peak at >1000 bp indicates large fragments are still 
present.  Isolates were also run on a genomic DNA (gDNA) tape to investigate the 
significance of the large peak prior to NGS. 
A 
 
B 
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Figure 3.8 Electropherogram using gDNA tape on mycoplasma DNA sonicated 
for 75 seconds to identify larger DNA fragments unsuitable for sequencing  
This electropherogram shows that the large peak observed using the high 
sensitivity tape represents a minimal number of fragments >1000 bp, with 
distribution peaking around 675 bp size fragments. The peaks towards the 
smaller fragment end of each electropherogram represent smaller fragments 
unsuitable for NGS.  
Using 1.8 x AMPure beads for size selection as previously described, also allows a 
“reverse clean-up” in which larger fragments (>1000 bp), recognised as being 
problematic in MiSeq sequencing, can be removed prior to NGS. 
3.3.4 Mycoplasma felis Sequence Analysis                                                                                   
3.3.4.1 Pre-Analysis Data Trimming 
Figure 3.9 demonstrates the improvement of sequence quality scores after 
trimming of Illumina adaptors and an additional 25 bp trim of reads prior to 
analysis.
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Figure 3.9 FastQC per Base Sequence Quality Report 
 
A 
B 
C 
A: raw data quality scores, prior to adapter trimming 
B: quality scores after adapter trimming (sequences of less than 80 bp were 
removed entirely) 
C: quality scores for paired sequence after trimming, size filtering and an 
additional 25 bp trim on both ends 
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Table 3.3 Number of trimmed reads generated by NGS for each of the clinical isolates selected for alignment to whole genome 
references and genes of interest 
Isolate 
Number of reads 
generated 
Number of reads aligned to M. 
cynos C142 whole genome 
Percentage of  reads aligned to 
M. cynos C142 whole genome 
10160 315,368 53,013 16.81 
15 382,298 62,702 16.4 
21 239,500 40,920 17.09 
24 186,718 28,737 15.39 
32 720,200 134,485 18.67 
3 7,445,148 1,337,951 17.97 
42 462,906 71,008 15.34 
46 293,742 46,434 15.81 
4 2,751,950 500,486 18.19 
5 1,148,860 198,946 17.32 
6 1,684,144 314,522 18.68 
8 539,708 36,699 6.8 
9 322,862 49,954 15.47 
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3.3.4.2 De novo assembly 
The de novo assembly of reference strain 10160 and the selected clinical isolates 
generated contigs averaging between 1368 and 4425 bp, however these contigs 
generated inconsistent results on BLAST and on close examination, much of the 
sequence was noted to be repetitive or non-coding with little depth of coverage.  
Unfortunately, lack of confidence in the accuracy of the contigs being generated 
in de novo assembly, and the time constraints of the project, left us unable to 
pursue further assemblies and their subsequent analyses at this stage. 
3.3.4.3 Alignments Using BLAST 
After inconsistent BLAST hits to the NCBI database were obtained from the 
generated contigs, trimmed original sequence reads were analysed with BLAST 
to the NCBI database and used for all subsequent analyses.  The trimmed reads 
returned consistent BLAST hits and allowed the selection of a reference genome.  
Mycoplasma cynos C142 (accession number HF559394) was the most common 
match using trimmed sequence reads generated from the Mycoplasma felis 
clinical isolates and reference strain.   
3.3.4.4 Alignments Using M. cynos as a Reference Genome 
Trimmed reads, from each clinical isolate in addition to the reference strain 
10160, were aligned in CLC to the M. cynos C142 whole genome which has been 
well characterised and annotated in NCBI.  Twelve M. felis isolates, 
demonstrating varying degrees of coverage (Figure 3.10), plus the reference 
isolate 10160 were selected for further analysis. 
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Figure 3.10 Representation of coverage of twelve Mycoplasma felis isolates 
and reference strain 10160 aligned to Mycoplasma cynos whole genome 
using CLC Genomics Workbench 7.5.1.
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Figure 3.11 Isolate 3 aligned to M. cynos whole genome, image represents alignment to whole genome, arrowed section shown in 
Figure 3.12 at higher magnification. 
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Figure 3.12 Isolate 3 aligned to M. cynos whole genome, image represents alignment between bases 1 and 250,000 of M. cynos 
(highlighted on Figure 3.11)
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3.3.4.5 Other Alignments 
Unmapped reads from isolate 3 were run on BLAST to identify if genetic 
sequence from any other organisms may be present, explaining why they did not 
map to M. cynos.  Unfortunately, using BLAST standard parameters for a 
nucleotide megablast, no hits were returned, with “no significant similarity” 
being found.  
Table 3.1 shows all mycoplasma whole genomes which were downloaded from 
NCBI for alignment, with the selected M. felis data, in CLC Genomic Workbench 
7.5.1. These whole genome alignments demonstrated sparse and varied coverage 
from the M. felis reads.  For example; M. felis reference strain 10160 
demonstrated mapping of between 2.8% (M. mycoides strain PG1) and 6.83% (M. 
fermentans) of reads to each mycoplasma whole genome tested, including an M. 
felis scaffold genome (Accession number KL370829), to which 3.24% of the 10160 
reads were mapped. M. cynos was significantly better with 16.8% of reference 
strain 10160 reads mapping to the M. cynos C142 genome, however this still 
leaves a substantial number of reads unmapped, thus preventing interpretation. 
Table 3.2 displays the individual genes of interest that were selected from NCBI 
for alignment to the M. felis sequence reads.  None of the genes of interest 
were shown to align convincingly with any of the M. felis isolates, again showing 
sparse coverage.  Upon investigation, the aligned areas appeared to be mostly 
repetitive, non-coding sequence.   
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Table 3.4 Mycoplasma cynos proteins and their genome locations; proteins 
aligned (partial or complete) with M. felis clinical isolates and reference 
strain 10160 are listed in bold.  
Protein Start Location End Location 
Lipoprotein 67434 69851 
ABC transporter permease 70370 73426 
ABC transporter ATP-binding protein 143200 145137 
ABC transporter ATP-binding protein 145146 146936 
Permease 191064 191285 
Lipoprotein signal peptidase 214681 215328 
Lipoprotein signal peptidase 215403 216692 
Peptide ABC transporter permease 269957 271117 
Peptide ABC transporter permease 271118 272425 
ABC transporter permease 288110 289141 
ABC transporter permease 289141 290172 
Lipoprotein 391576 394650 
Lipase 408928 415338 
Nuclease, enda/nucm family 477694 478431 
Uncharacterised lipoprotein MCAP_0231 622506 624263 
Lipoprotein 626746 627855 
Intergrase 727225 728148 
DNA/RNA nuclease 802044 802622 
Orfg1 838478 839020 
Nuclease 852690 854018 
Peptidase M17 922571 923950 
Membrane nuclease (Mnua) 967642 968136 
P60-like protein 972628 973872 
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Some regions of interest corresponding to the proteins as shown in Table 3.4 (in 
bold) were identified following alignment of the sequenced isolates to the M. 
cynos genome.  The majority of these alignments correspond to transporter 
permease proteins which are integral components of the cell membrane, 
facilitating the movement of molecules in and out of the cell.  Peptidase M17 
refers to a leucyl aminopeptidase (LAP), a member of the M17 metallo-peptidase 
family of proteins (Bhosale et al., 2010).  Mycoplasma felis was also identified as 
having sequence homology with a lipoprotein signal peptidase annotated in M. 
cynos.   
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3.4 Discussion 
In sequencing the M. felis genome, there were two purposes: to determine if any 
antimicrobial resistance, phenotypically observed in earlier experimental work, 
could be correlated with known antimicrobial resistance genotypes; and also to 
use NGS technology as a means of screening the available clinical isolates for 
genes known to increase virulence in other mycoplasmas including those 
associated with immunomodulation and adhesion in host cells. 
The optimisation of mycoplasma template for input and the library preparations 
themselves involved significant time at the bench leaving limited time for 
detailed analyses of the generated data sets.  The results described here are 
therefore preliminary and more thorough analyses of the data may enable 
additional conclusions to be drawn.  
Ideally, for accurate and workable NGS data to be obtained, the DNA library 
should be representative of the sample, with evenly distributed reads across the 
entire genome.  Currently, the whole genome for M. felis  is unavailable 
therefore it was considered that de novo assembly would be of benefit, even if it 
was only achieved for the reference strain, it would allow that scaffold to be 
used as a reference for the clinical isolates along with any future work.  The de 
novo assembly of the M. felis genome was unsuccessful and contigs obtained 
through de novo assembly in CLC when run on BLAST returned numerous (non-
mycoplasma) bacterial hits and only minimal mycoplasma hits, with very sparse 
alignments.  Accurate de novo assembly requires reasonable overlap between 
the generated reads from a given sample depending on the software parameters 
used.  The high GC content and volume of repetitive non-coding sequence in 
mycoplasmas (Rocha and Blanchard, 2002, Shu et al., 2011) may also 
havehindered accurate de novo assembly.  For the de novo assembly of the M. 
cynos C142 genome, a combination of sequencing technologies were required in 
order to allow generation of a scaffold (Walker et al., 2013), indicating that the 
difficulty experienced in our study is not unusual. 
Fragment size distribution was shown to be within range using the TapeStation, 
but showed a marked level of degradation, indicated by a lower size range of 
fragments unsuitable for NGS.  It would be interesting to sequence these 
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fragments and determine if, together with the larger fragments, they provide a 
more whole representation of the M. felis genome.  
Although the DNA concentration was determined for each of the isolates and for 
the pooled isolates prior to sequencing, this unfortunately gives no indication 
regarding the quality or diversity of the DNA, or if it is capable of clustering on 
the flow cell during NGS.  Robin et al. highlighted that the quantification 
techniques used in this project could be comparable to quantitative PCR, 
however their study used libraries proven to be concentrated and homogenous 
{Robin, 2016 #694} which cannot be said for the mycoplasma libraries used in 
this study.  A droplet digital PCR machine is available within the laboratory and 
would use only a minimal amount of the DNA eluate, however during the 
practical work, time and cost were factors and this machine was not utilised.  
Given that one mycoplasma extract generated at least 3 times more reads than 
the others in this study (Table 3.3), it seems the droplet digital PCR is something 
which should have been prioritised. 
Mapping to a reference genome allows differentiation between real sequences 
and possible variants to those of errors in assembly, thus providing insight on 
mapping quality.  However, if no reference genome is available, or the 
generated sequence is not in the reference genome, possibly due to genome 
insertions or rearrangements in the template DNA, then no alignment will be 
made.  It is acknowledged that mycoplasmas are highly mutable and contain 
substantial amounts of low complexity sequences.  Carvalho et al. investigated 
mycoplasma genomes, hypothesising that a minimal genome would require only 
minimal DNA repair.  It was actually identified that mycoplasmas lack many of 
the typical mismatch repair enzymes, their primary repair mechanism being 
nucleotide excision repairs.  The result is an increase in DNA replication errors 
and thus, mutagenesis (Carvalho et al., 2005), indicating alignments may well 
prove difficult. 
Interestingly, M. cynos was a much closer match to the generated reads in BLAST 
than other, phylogenetically closer, mycoplasmas within the fermentans group. 
Mycoplasma cynos has been identified as a respiratory pathogen in dogs (Walker 
et al., 2013), therefore, as it demonstrated the closest sequence homology to 
the M. felis isolates, it wouldn’t be unreasonable to expect M. felis to be 
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pathogenic in cats.  However, only 16.8% of the 10160 reference isolate reads 
aligned to the M. cynos whole genome. The unmapped reads from isolate 3 
disappointingly returned no BLAST matches, however within the BLAST website; 
it does explain that results like this are common for low complexity queries, 
with filters within the program which mask low complexity regions.  It would be 
interesting to take time adjusting these filters within BLAST in order to run a 
more thorough analysis. 
The depth of coverage, of isolates aligned to the M. cynos whole genome (Fig 
3.8), was notably variable; this may be explained by the variable number of 
reads generated for each isolate, which in turn may be explained by the quality 
of the original samples.  The process of DNA extraction required lengthy 
optimisation after very low yields of DNA were obtained.  The optimisation 
enabled sufficient DNA to be harvested for NGS; however, the yield was still low 
(0.6 – 1.7 ng/µL) and required a library preparation kit designed for low input 
DNA templates (Rubicon Genomics). 
Although such kits are available, starting template concentration is one of the 
most influential factors in successful library preparation; too few copies of the 
template sequence yields a low complexity library.  Amplification whilst useful, 
will only amplify the available DNA, therefore starting with a low complexity 
library will only produce more of the same limited fragments (Song et al., 2013, 
van der Walt, 2015, Vincent et al., 2016).  Amplification bias has also been 
identified as a potential problem wherein any differences in synthesis efficiency, 
through the cyclic nature of PCR, are multiplied exponentially, thus creating an 
uneven representation of sequences (van der Walt, 2015). 
For this reason, large research and development companies such as 
KapaBiosystems (Cape Town, South Africa) recommend optimising the protocol 
provided with any commercially available library preparation kit, in order to 
ensure the most efficient conversion of DNA template to library fragments 
thereby maintaining library complexity (van der Walt, 2015).  For this project, 
the library preparation was carried out in accordance with the manufacturer’s 
instructions, with no specific optimisation.  It would be interesting to know if 
other researchers have worked with the Rubicon kit used here, and if they 
observed any difference in coverage following optimisation. 
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The M. felis data showed some homology with a selection of M. cynos genes 
including those encoding ABC transporter permeases, ATP binding proteins and a 
lipoprotein signal peptidase.  These proteins have been identified in a variety of 
mycoplasma species, with some specificity in target molecules, indicating they 
are well conserved and likely essential to mycoplasma survival.  Some studies 
have identified these proteins in the uptake of iron bound to transferrin or 
chelates, flagging them as potential virulence factor (Sanders et al., 1994, Li et 
al., 2011).  The alignment of trimmed M. felis reads to the peptidase M17 region 
of the M. cynos genome indicates the presence of this gene, or a gene which 
shares significant sequence homology, within the M. felis genome.   
Of particular interest in the alignment was the identification of a lipoprotein 
signal peptidase.  These signal peptidases behave as proteases catalysing the 
cleavage of prolipoproteins to release signal peptides.  There was no indication 
of which prolipoprotein this protease corresponds to.  Further analysis would be 
useful as lipoproteins have been identified as an important marker of virulence 
in other mycoplasmas, aiding in colonisation and host immunomodulation, (Razin 
et al., 1998, Into et al., 2002, Sasaki et al., 2002, Zuo et al., 2009) thus their 
identification in M. felis would allow further molecular characterisation. 
Peptidase M17 are cytoplasmic exopeptidases which have been well 
characterised in other prokaryotic and eukaryotic organisms in which they have 
been identified and have been established as cell maintenance enzymes, 
hydrolysing leucine substrates, having proteolytic properties and a role in DNA 
binding (Mitchell et al., 2014).  Their exact role in cellular metabolism is still 
undefined and within mycoplasma research has not gone further than identifying 
the presence of the encoding gene.   
A resistant phenotype was not observed during antimicrobial susceptibility 
testing, and so identifying genetic markers of resistance was disappointingly 
undirected.  It is worth noting; however, that phenotype was recorded only after 
one passage.  It has been demonstrated that resistance may be induced in vitro 
(Gautier-Bouchardon et al., 2002), therefore a selection of resistance genes, 
identified in other mycoplasmas, were used as references for alignments with 
the generated M. felis data in order to identify the presence of resistance genes 
in M. felis (clinical isolates and reference strain 10160) which may not have 
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been expressed at the time of culture.  None of the selected resistance genes 
were identified, either within the M. felis clinical isolates, or the reference 
strain, supporting the earlier phenotype data of no antimicrobial resistance ( 
emerging or otherwise) in the M. felis genome.  Given the mutability of 
mycoplasmas and their potential for recombination, it would be prudent to 
further explore this area. 
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Chapter IV                                                                                                
Discussion 
The aim of this study was to incorporate microbiological investigations with cell-
based infection studies and NGS technology to determine if M. felis should be 
treated when isolated from cats.  By investigating antimicrobial susceptibility 
patterns and observation of a cell-line infected with M. felis, a phenotype would 
be available which could be further studied using a genotypic assessment, in 
order to correlate phenotype and genotype as well as identify any genetic 
potential for virulence.  Time did not allow for the entire project to be 
completed, with the infection studies being sacrificed in order to complete the 
antimicrobial susceptibility testing and gene analysis.  This was unfortunate as 
the cell-based data could have given further insight into M. felis interactions 
with host cells, potentially identifying virulence and pathogenicity factors. 
The macrolides (erythromycin and azithromycin) proved to be least effective 
across all isolates.  Interestingly, of the macrolide resistance genes selected as 
references, M. felis aligned with none of them;however, the list was not 
exhaustive.  Given that the isolates spanned over forty years and all had similar 
susceptibility to the macrolides, this can’t be described as novel or emerging, 
indicating it’s not an evolutionary or acquired trait, but something inherent.  
Other mycoplasma susceptibility studies have demonstrated that macrolides are 
effective in vitro, with significantly lower MIC values than those obtained in this 
research (Whithear et al., 1983, Schultz et al., 2012).  It would be interesting to 
investigate the cause of this decreased susceptibility in M. felis; using a larger 
selection of macrolide resistance genes for alignment may be of benefit, and 
previous studies have described inducing resistance to erythromycin in as little 
as 2-3 passages (Gautier-Bouchardon et al., 2002).  Repeating this experiment 
with the M. felis isolates could perhaps create a selected population for 
sequencing and analysis. 
During this research, it should be noted that only ocular isolates were recovered 
for investigation; however, during sequence analysis and the search for an 
appropriate reference genome for alignments, the genome with closest 
homology in BLAST was that of M. cynos, a pathogen associated with canine 
infectious respiratory disease (Chalker et al., 2004). 
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Numerous studies have shown that M. felis may be present in the respiratory 
tract of clinically healthy cats as well as those showing signs of respiratory 
infection (Spradbrow et al., 1970, Foster et al., 1998, Binns et al., 2000, 
Chandler and Lappin, 2002, Bannasch and Foley, 2005, Helps et al., 2005, 
Johnson et al., 2005, Holst et al., 2010).  Thus, defining M. felis as a pathogen 
of the respiratory tract has proven troublesome.   
There is evidence that mycoplasma infection increases susceptibility to further 
infection (Ciprian et al., 1988) however, if M. felis is a commensal organism of 
the feline respiratory tract, admittedly likely with the potential to become an 
opportunistic pathogen, then it is worth considering which organism created the 
opportunity – which organism is the primary pathogen?  Potentially, feline 
respiratory viruses such as feline herpesvirus (FHV) and feline calicivirus (FCV) 
may be the primary or secondary pathogens.  Of the ocular isolates utilised in 
this study, co-infections with FHV and FCV were identified on original 
examination of the specimens, indicating they are capable of co-infecting with 
M. felis. 
The infection study would have allowed the detection of cytopathic effect 
during mycoplasma infection, which would have allowed us to determine if M. 
felis interferes with host defences, which would certainly predispose to further 
infection.  Having this information would provide further important evidence on 
directing therapy.   
Observation of the mycoplasmas in cell culture may also have provided further 
guidance for the genetic analyses – perhaps identifying if M. felis is one of the 
mycoplasmas capable of becoming intracellular and thus directing a search for 
attachment organelle and associated proteins.  It would also have allowed 
comparison of isolates; throughout this study, little variance in results has been 
observed, with antimicrobial susceptibilities being similar and no resistance 
demonstrated, and genetic analyses only varying in the number of reads 
generated and available for alignments.  During culture, growth of numerous 
isolates was surprisingly faster than expected, even for isolates with identical 
VCCs, and haemolytic activity was varied with some isolates requiring different 
media for growth and observation.  Perhaps in cell culture it would have been 
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easier to examine these qualities further and elucidate if they affect 
pathogenicity. 
The minimal genome of mycoplasmas is well documented, with numerous studies 
attempting to elucidate the minimal gene complement and establish the 
essential genes (Fraser et al., 1995, Rocha and Blanchard, 2002, Pich et al., 
2006, Gibson et al., 2008, Shu et al., 2012).  A pan-genome analysis by Liu et al. 
(2012) estimated that across the mycoplasma genus, more than 8000 genes exist.  
Across the twenty species and strains of mycoplasmas examined, only 196 genes 
were shared by all, with around half of those dedicated to genetic processes 
such as translation or ribosomal structure.  In the same study, three strains of M. 
hyopneumoniae were shownare 95% of genes (Liu et al., 2012).   
There are multiple areas which could benefit from further investigation.    One 
priority would be to complete the de novo assembly of the M. felis genome/s; 
however, an accurate full genome de novo assembly of such a size, in itself is a 
massive undertaking.  This could constitute a separate bioinformatics project.   
There are scaffolds available on NCBI for M. felis (NCBI Reference Sequence 
NZ_JNKA00000000.1) and this could be indicative that a whole genome assembly 
may be forthcoming or at least could be used to help generate an accurate 
assembly.  To undertake such a project perhaps further depth of sequence would 
be advantageous and also to combine the various isolates’ sequence to try and 
achieve a representative data set that will match existing scaffolds available.  
Cole (1967) described the isolation and culture of M. felis from the eye of a cat 
with severe conjunctivitis.  The isolate was then used to successfully infect the 
conjunctiva of kittens before being isolated again and proven to be identical to 
the original isolate, thus defining Koch’s postulates.  This is noteworthy; 
however, kittens lack a fully developed immune system, leaving them more 
susceptible to, and less able to clear infections.  Numerous studies have 
investigated the conjunctival flora of cats (Shewen et al., 1980, Haesebrouck et 
al., 1991b, Haesebrouck et al., 1991a, Espínolaz and Lilenbaum, 1996, Hartmann 
et al., 2010), and reported that M. felis was isolated only in cases of 
symptomatic conjunctivitis.  This suggests that M. felis could be considered an 
ocular pathogen and that treatment of such infections may be justified. 
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Within this study no definitive virulence factors could be identified. Of the 
selection of virulence genes identified in mycoplasmas, M. felis appears to 
possess none of them.  In fact, several whole genomes of the mycoplasmas 
established as primary pathogens, were used for alignment in this study, 
including M. fermentans, M. bovis, M. pneumoniae and M. genitalium with M. 
felis failing to align reasonably with any of them.  It would be prudent to 
acknowledge the limitations of the gene analysis in this study – the virulence 
genes selected for examination were not exhaustive, and given the highly 
mutable genome of mycoplasmas, it would be of benefit to further investigate 
this area in order to definitively identify the pathogen status of M. felis.  
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Appendix 1.  Antimicrobial Dilutions Set Up for MIC Testing 
a End Point Control – liquid browth adjusted to pH 6.8 thus creating a colour change to which growth could be matched  
b Growth Control – undiluted inoculum added to liquid browth to indicate viable organisms and rate of growth 
c Sterility Control – liquid broth incubated alone to ensure no contamination of growth media 
d,e Solvents used to dissolve antimicrobials (dH2O and 100% Ethanol) were added to inoculum to ensure they did not inhibit 
growth 
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Appendix 2. MIC Results for all Clinical Isolates and Strain D8 
 MINIMUM INHIBITORY CONCENTRATION 
Sample AMP AZI DOXY ENRO ERY OTC PRADO 
3 n/a 8 8 4 64 2 0.0625 
4 n/a 4 4 8 64 1 0.0625 
5 n/a 8 0.03125 0.125 >64 0.0625 0.0625 
6 n/a 4 1 1 16 1 0.03125 
7 n/a 16 0.03125 2 32 0.5 0.25 
8 n/a 1 0.0625 0.125 32 0.0625 0.03125 
9 n/a 2 0.0625 4 32 1 0.25 
10 n/a 32 0.03125 0.125 64 0.5 0.03125 
11 N/A 32 0.03125 0.125 64 1 0.03125 
12 n/a 16 0.03125 2 64 1 0.125 
13 n/a 4 0.0625 0.0125 32 0.03125 0.03125 
14 n/a 4 0.03125 0.0125 16 0.03125 0.03125 
15 n/a 64 0.0625 0.0625 >64 1 0.03125 
16 n/a 4 0.03125 0.125 32 0.5 0.03125 
17 n/a 16 0.03125 0.125 16 0.5 0.03125 
18 N/A 16 0.03125 0.03125 64 0.5 0.03125 
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 MINIMUM INHIBITORY CONCENTRATION 
Sample AMP AZI DOXY ENRO ERY OTC PRADO 
19 n/a 8 0.03125 0.0625 8 1 0.03125 
20 N/A 2 0.03125 0.125 32 0.5 0.03125 
21 n/a 32 0.0625 0.0625 >64 1 0.03125 
22 n/a 32 0.03125 0.125 64 0.5 0.03125 
23 n/a 8 0.125 0.03125 32 0.5 0.03125 
24 n/a 4 0.0625 0.125 16 0.25 0.03125 
25 N/A 4 0.03125 0.125 64 0.5 0.03125 
26 n/a 2 0.03125 0.25 32 1 0.03125 
27 N/A 16 0.03125 0.125 64 0.25 0.03125 
28 N/A 32 0.03125 0.125 64 0.5 0.03125 
29 n/a 16 0.0625 0.125 32 1 0.03125 
30 n/a 4 0.03125 0.03125 8 1 0.03125 
31 n/a 8 0.03125 0.125 64 1 0.03125 
32 n/a 32 0.03125 0.125 64 1 0.03125 
33 n/a 16 0.03125 0.125 64 1 0.03125 
34 n/a 4 0.03125 0.125 64 0.5 0.03125 
35 n/a 4 0.0125 0.25 16 1 0.03125 
36 n/a 2 0.03125 0.03125 32 0.5 0.03125 
37 n/a 8 0.03125 0.03125 64 0.5 0.03125 
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 MINIMUM INHIBITORY CONCENTRATION 
Sample AMP AZI DOXY ENRO ERY OTC PRADO 
38 n/a 16 0.03125 0.03125 64 0.5 0.03125 
39 n/a >64 0.0625 0.125 >64 0.5 0.03125 
40 n/a 32 0.03125 0.125 64 0.5 0.03125 
41 n/a 4 0.03125 0.5 8 1 0.125 
42 n/a 8 0.03125 0.0125 16 0.5 0.03125 
43 n/a 8 0.03125 0.125 64 0.5 0.03125 
44 n/a 16 0.03125 0.03125 32 0.25 0.03125 
45 n/a 2 0.03125 0.0125 8 0.03125 0.03125 
46 n/a 16 0.03125 0.125 64 1 0.03125 
47 n/a 8 0.125 0.125 64 2 0.3125 
48 n/a 4 0.0625 0.125 16 0.5 0.03125 
D8 (KR) n/a 8 0.03125 0.25 64 1 0.03125 
NE01 N/A 8 0.03125 0.125 64 0.5 0.03125 
NE02 n/a 2 0.0625 2 32 1 0.03125 
NE03 n/a 16 0.03125 0.125 64 1 0.03125 
NE04 n/a 32 0.125 0.125 >64 1 0.03125 
 
